Dual GLP-1 and glucagon agonist peptides with improved biological stability

By developing GLP-1 and glucagon dual agonist peptides with specific sequence modification and lipid modification, the problem of insufficient biostability and duration of action in existing therapies is solved, achieving efficient blood sugar control for weekly administration and Weight loss effect, suitable for the treatment of type 2 diabetes and non-alcoholic steatohepatitis.

CN118974080APending Publication Date: 2024-11-15MEDIMMUNE LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380031121.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-07
Filing Date
2023-02-06
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing GLP-1 and glucagon analog therapies require continuous self-medication, resulting in low patient compliance and insufficient biostability and duration of action, making it difficult to effectively manage type 2 diabetes and obesity.

Method used

A dual agonist peptide of GLP-1 and glucagon that improves biostability and duration of action has been developed, which enhances the stability and activity of the peptide through specific amino acid sequence modification and lipid modification, and can be administered weekly once.

Benefits of technology

This dual agonist peptide significantly improves biostability and duration of action, enhances the effect on blood sugar control and weight loss, improves patient compliance and quality of life, and is suitable for the treatment of type 2 diabetes and non-alcoholic steatohepatitis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118974080A_ABST
    Figure CN118974080A_ABST
Patent Text Reader

Abstract

Provided herein are dual GLP-1 and glucagon agonists having improved biological stability (e.g., proteolytic stability) and duration of action. The peptide may be administered once weekly, for example.
Need to check novelty before this filing date? Find Prior Art

Description

Background Art

[0001] The incidence of obesity and diabetes is rising in epidemic proportions. Diabetes is characterized by high levels of blood sugar caused by defects in insulin production, insulin action, or both. Type 2 diabetes (T2DM) accounts for approximately 90 to 95 percent of all diagnosed diabetes cases, and the risk of type 2 diabetes increases with increasing body weight. The prevalence of type 2 diabetes in those affected by obesity is three to seven times that of normal weight adults, and a body mass index (BMI) greater than 35 kg / m 2 However, weight loss can improve, control, or cure type 2 diabetes.

[0002] Glucagon and glucagon-like peptide-1 (GLP-1) are derived from pre-proglucagon, a 158 amino acid precursor polypeptide that is processed in different tissues to form a variety of different proglucagon-derived peptides, including glucagon, glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2), and oxyntomodulin (OXM), which are involved in a wide variety of physiological functions, including glucose homeostasis, insulin secretion, gastric emptying, and intestinal growth, as well as regulating food intake. Glucagon is a 29 amino acid peptide corresponding to amino acids 33 to 61 of proglucagon (53 to 81 of pre-proglucagon), while GLP-1 is produced as a 37 amino acid peptide corresponding to amino acids 72 to 108 of proglucagon (92 to 128 of pre-proglucagon). GLP-1 (7-36) amide or GLP-1 (7-37) acid are biologically active forms of GLP-1 that exhibit substantially equivalent activity at the GLP-1 receptor.

[0003] Glucagon is produced by the pancreas and interacts with the glucagon receptor ("glucR"). Glucagon acts in the liver to raise blood sugar via gluconeogenesis and glycogenolysis. When blood sugar begins to fall, glucagon signals the liver to break down glycogen and release glucose, causing blood sugar levels to rise toward normal levels.

[0004] Compared to glucagon, GLP-1 has different biological activities. It is secreted from intestinal L cells and binds to the GLP-1 receptor. Its activities include stimulating insulin synthesis and secretion, inhibiting glucagon secretion, and inhibiting food intake.

[0005] Both glucagon and GLP-1, acting as agonists at their respective receptors, have been shown to be effective in reducing weight. Certain GLP-1 analogs being marketed or in development for the treatment of obesity include, for example, liraglutide (from Novo Nordisk ) and Semaglutide (from Novo Nordisk ). Glucagon / GLP-1 dual agonist peptides (e.g., cotadutide) are also known and are in clinical development for the treatment of diabetes, obesity, and non-alcoholic steatohepatitis (NASH). However, all of these proposed therapies involve chronic self-medication, which requires patient compliance over a sustained period of time. Other peptides, such as amylin analogs, are also being considered for the treatment of obesity, excess food intake, and diabetes (WO 2018 / 046719).

[0006] Thus, there remains a need for treatments that can agonize both GLP-1 and glucagon function, e.g., to improve glycemic control, reduce weight, treat type 2 diabetes (T2DM), and / or treat NASH, while minimizing the burden associated with administration to improve patient compliance and quality of life. Summary of the invention

[0007] Provided herein are GLP-1 and glucagon dual agonists with improved biological stability (e.g., proteolytic stability) and duration of action. For example, compared to semaglutide (H(Aib)EGTFTSDVSSYLEGQAAX20EFIAWLVRGRG-acid wherein X20 = ​​Lys[O2Oc-O2Oc-γE-C18 diacid] (SEQ ID NO: 539)) and / or cotyledon (HSQGTFTSDX10SEYLDSERARDFVAWLEAGG-acid wherein X10 = Lys[ε-γE-palmitoyl] (SEQ ID NO: 538)), the GLP-1 and glucagon dual agonist peptides provided herein may have improved properties. Therefore, the GLP-1 and glucagon dual agonist peptides provided herein may be administered once a week.

[0008] Certain aspects of the present disclosure relate to peptides comprising the following sequence: H-X2-X3-G-X5-X6-TSD-X10-S-X12-α-methyl-phenylalanine (αMePhe)-L-X15-X16-X17-X18-A-X20-X21-X22-X23-X24-X25-X26-X27-X28-X29-X30-X31-Z, wherein X2 is aminoisobutyric acid (Aib), S or A, X3 is Q, H or E, X5 is T or S, X6 is F or αMePhe, and X10 is V , K or Y, X12 is K, E or S, X15 is D or E, X16 is T, S or G, X17 is K, R, E or Q, X18 is R or A, X20 is R, K or Q, X21 is D or E, X22 is αMePhe or F, X23 is V or I, X24 is Q or A, X25 is Aib or W, X26 is L or I, X27 is L, A, E, V or M, X28 is E, N, A, R or K, X29 is Aib, T or G, X30 is G, R or absent, X31 is G or absent, and Z is amide or acid (SEQ ID NO: 540).

[0009] In some aspects, X2 is Aib. In some aspects, X3 is Q. In some aspects, X3 is H. In some aspects, X5 is T. In some aspects, X5 is S. In some aspects, X6 is F. In some aspects, X6 is αMePhe. In some aspects, X10 is V. In some aspects, X12 is K. In some aspects, X15 is D. In some aspects, X16 is T. In some aspects, X16 is S. In some aspects, X17 is K. In some aspects, X17 is R. In some aspects, X18 is R. In some aspects, X18 is A. In some aspects, X20 is R. In some aspects, X20 is K. In some aspects, X21 is D. In some aspects, X22 is F. In some aspects, X22 is αMePhe. In some aspects, X23 is V. In some aspects, X24 is Q. In some aspects, X25 is W. In some aspects, X25 is Aib. In some aspects, X26 is L. In some aspects, X26 is I. In some aspects, X27 is L. In some aspects, X27 is A. In some aspects, X28 is E. In some aspects, X28 is N. In some aspects, X29 is Aib. In some aspects, X29 is T. In some aspects, X30 is G. In some aspects, X30 is absent. In some aspects, X31 is absent. In some aspects, Z is an amide. In some aspects, Z is an acid.

[0010] In some aspects, X2 is Aib, X12 is K, and X24 is Q. In some aspects, X16 is T, X17 is K, X27 is L, X28 is E, and X29 is Aib. In some aspects, X3 is Q, X5 is T, X6 is F, X10 is V, X12 is K, X15 is D, X16 is T, X17 is K, X18 is R, X20 is R, X21 is D, X22 is F, X23 is V, X24 is Q, X25 is W, X26 is L, X27 is L, X28 is E, X29 is Aib, X30 is G, X31 is absent, and Z is an acid. In some aspects, X3 is H, X5 is S, X6 is αMePhe, X10 is V, X12 is K, X15 is D, X16 is S, X17 is R, X18 is A, X20 is K, X21 is D, X22 is αMePhe, X23 is V, X24 is Q, X25 is Aib, X26 is I, X27 is A, X28 is N, X29 is T, X30 is absent, X31 is absent, and Z is amide.

[0011] In some aspects, one or more lysine residues are acylated. In some aspects, the lysine at position 17 is acylated. In some aspects, the lysine at position 20 is acylated.

[0012] In some aspects, one or more lysine residues are lipidated. In some aspects, the lysine at position 17 is lipidated. In some aspects, the lysine at position 20 is lipidated.

[0013] In some aspects, the lipid is selected from octadecanedioic acid (C18 diacid) and eicosanedioic acid (C20 diacid). In some aspects, the lipid is octadecanedioic acid (C18 diacid). In some aspects, the lipid is eicosanedioic acid (C20 diacid). In some aspects, the lipid is connected to the epsilon amino group of lysine at position 17 or 20 via a linker.

[0014] In some aspects, the linker is ((O2Oc)-(O2Oc)-γE) or ((O2Oc)-(O2Oc)-γE-γE) in the C-terminal to N-terminal direction. In some aspects, the linker is ((O2Oc)-(O2Oc)-γE) in the C-terminal to N-terminal direction. In some aspects, the linker is ((O2Oc)-(O2Oc)-γE-γE) in the C-terminal to N-terminal direction. In some aspects, the linker is attached to the epsilon amino group of the residue at position 17 or 20.

[0015] Certain aspects of the present disclosure relate to peptides comprising the sequence of H-Aib-QGTFTSDVSK-αMePhe-LDTKRARDFVQWLLE-Aib-G-acid (SEQ ID NO: 541).

[0016] In some aspects, the lysine at position 17 is acylated and lipidated, the lipid is linked to the acylated lysine via the epsilon amino group of the acylated lysine linked to a ((O2Oc)-(O2Oc)-γE) linker in the C-terminal to N-terminal direction, and the lipid is octadecanedioic acid (C18 diacid). In some aspects, the lysine at position 17 is acylated and lipidated, the lipid is linked to the acylated lysine via the epsilon amino group of the acylated lysine linked to a ((O2Oc)-(O2Oc)-γE) linker in the C-terminal to N-terminal direction, and the lipid is eicosanedioic acid (C20 diacid).

[0017] Certain aspects of the present disclosure relate to a peptide comprising the sequence H-Aib-HGS-αMePhe-TSDVSK-αMePhe-LDSRAAK(ε-(O2Oc)-(O2Oc)-γE-C18 diacid)20-D-αMePhe-VQ-Aib-IANT-amide (SEQ ID NO: 228).

[0018] Certain aspects of the present disclosure relate to a peptide comprising the sequence H-Aib-HGS-αMePhe-TSDVSK-αMePhe-LDSRAAK(ε-(O2Oc)-(O2Oc)-γE-γE-C20 diacid)20-D-αMePhe-VQ-Aib-IANT-amide (SEQ ID NO: 233).

[0019] In some aspects, the peptide binds to a GLP-1 receptor (GLP-1R), to a glucagon receptor (GCGR), or to both a GLP-1 receptor and a glucagon receptor. In some aspects, the GLP-1R is a human GLP-1R. In some aspects, the GCGR is a human GCGR.

[0020] In some aspects, the peptide is an agonist of GLP-1 activity, an agonist of glucagon activity, or an agonist of both GLP-1 activity and glucagon activity. In some aspects, the peptide has increased resistance to proteolysis relative to the natural ligands of GLP-1R and / or GCGR.

[0021] In some aspects, the peptide is isolated.

[0022] In some aspects, the peptide has at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% intact peptide remaining after incubation with a protease at 37° C. for 5 minutes, 10 minutes, 15 minutes, 30 minutes, 2 hours, 4 hours, or 24 hours. In some aspects, the protease is selected from enkephalinase, pepsin, pancreatin, simulated gastric fluid with pepsin, and simulated intestinal fluid with pancreatin.

[0023] In some aspects, the peptide has a half-life of at least 45 hours, at least 50 hours, at least 60 hours, at least 70 hours, at least 80 hours, at least 90 hours, at least 100 hours, at least 110 hours, at least 120 hours, or about 130 hours in cynomolgus monkeys after intravenous administration. In some aspects, the peptide has a subcutaneous bioavailability of at least 75%, at least 80%, at least 90%, or about 95% in cynomolgus monkeys.

[0024] In some aspects, provided herein is a pharmaceutical composition comprising the peptide. In some aspects, the composition is a solid composition. In some aspects, the composition is a liquid composition.

[0025] In some aspects, provided herein is a method for treating or preventing a disease or condition caused by or characterized by being overweight, wherein the method comprises administering an effective amount of any peptide or composition provided herein to a subject in need of treatment. In some aspects, the disease or condition is obesity. In some aspects, the disease or condition is type 2 diabetes.

[0026] In some aspects, provided herein are methods of treating or preventing nonalcoholic steatohepatitis (NASH), wherein the method comprises administering to a subject in need of treatment an effective amount of any peptide or composition provided herein.

[0027] In some aspects of the methods provided herein, administration is performed by injection. In some aspects of the methods provided herein, administration is oral. In some aspects of the methods provided herein, administration reduces the weight of the subject, increases the insulin secretion of the subject, delays the gastric emptying of the subject, reduces the food intake of the subject, enhances the mitochondrial function of the subject, inhibits the de novo lipogenesis of the subject, reduces the HbA1c of the subject, enhances the fat oxidation of the subject, reduces the oxidative stress of the liver mitochondria of the subject, reduces the fatty degeneration of the subject, reduces the fibrosis of the subject, reduces the glycogen synthesis of the subject, increases the gluconeogenesis of the subject, prevents the disease progression of the subject, reverses the fibrosis of the subject and / or reduces the death risk of the subject due to cirrhosis, hepatocellular carcinoma and / or cardiorenal disease. In some aspects of the methods provided herein, the subject is human. In some aspects of the methods provided herein, the peptide is administered about once a week. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1A-1G Figure 2 is a diagram depicting the following exemplary lipids: Eicosanedioic acid (C20 diacid) ( Figure 1A ), octadecanedioic acid (C18 diacid) ( Figure 1B ), stearoyl ( Figure 1C ), heptadecanoyl ( Figure 1D ), palmitoyl ( Figure 1E ), myristoyl ( Figure 1F ) and laurel ( Figure 1G ).

[0029] Figure 2A-2F To depict the following attached to Figure 1A-1G Figure 1 shows an exemplary linker for a lipid depicted in FIG: 2-(2-(2-aminoethoxy)ethoxy)acetic acid (O2Oc) ( Figure 2A )、(O2Oc)-(O2Oc)( Figure 2B )、(O2Oc)-γE-(O2Oc)( Figure 2C )、(PEG)2-(PEG)2-γE-γE( Figure 2D )、(PEG)2-γE-(PEG)2-γE( Figure 2E ), γ-glutamate (γE) ( Figure 2F ),γE-(O2Oc)( Figure 2G )、γE-(O2Oc)-(O2Oc)( Figure 2H )、γE-(O2Oc)-γE-(O2Oc)( Fig.2I ),γE-(PEG)2-(PEG)2( Figure 2J ), γE-(PEG)2-γE-(PEG)2 (Figure 2K), γE-(PEG)4( Figure 2L )、γE-γE( Figure 2M)、γE-γE-(O2Oc)( Figure 2N )、γE-γE-(O2Oc)-(O2Oc)( Fig.2O ),γE-γE-(PEG)12( Figure 2P )、γE-γE-(PEG)2-(PEG)2( Figure 2Q )、γE-γE-(PEG)2-γE-γE( Figure 2R )、γE-γE-(PEG)4( Figure 2S ),γE-γE-(PEG)8( Figure 2T ), γE-γE-(O2Oc)-(O2Oc)-γE-γE( Figure 2U ) and (PEG)2-(PEG)2-γE( Figure 2V ). All linkers are shown with the N-terminus on the left and the C-terminus on the right.

[0030] Figure 3A-Figure 3P is a diagram depicting the following exemplary unnatural amino acids: 2-amino-2-methylpropanoic acid (Aib) ( Figure 3A )、(S)-2-amino-2-methyl-3-phenylpropionic acid (αMePhe) Figure 3B )、(S)-2-amino-3-hydroxy-2-methylpropanoic acid (αMeSer)( Figure 3C )、D-glutamine (dGln) ( Figure 3D ), β-dimethylglutamine (β-dimethyl Gln) ( Figure 3E )、(S)-2,5-diamino-2-methyl-5-oxopentanoic acid (αMeGln)( Figure 3F )、D-serine (dSer) Figure 3G ), methyl-L-glutamine (N-MeGln) ( Figure 3H )、((1H-imidazol-4-yl)methyl)glycine (NHis)( Fig. 3I )、1-aminocyclopropane-1-carboxylic acid (Acpr)( Figure 3J ), 1-aminocyclobutane-1-carboxylic acid (Acbu) (Figure 3K), N 6 -Acetyl-L-lysine (Ac-Lys) Figure 3L )、(S)-2-amino-5-guanidino-3,3-dimethylpentanoic acid (β-dimethylArg) ( Figure 3M )、(S)-2-amino-3,3-diphenylpropionic acid (Dip)( Figure 3N )、(S)-2-amino-3-cyclohexylpropionic acid (Cha)( Fig.3O )、(S)-2-aminohexanoic acid (Nle)( Figure 3P )、(S)-3-([1,1'-diphenyl]-4-yl)-2-aminopropionic acid (Bip)( Figure 3Q )、1-methyl-L-tryptophan (1-methyl-Trp) ( Figure 3R ) and (S)-2-amino-3-(5-bromo-1H-indol-3-yl)propanoic acid (5-Br-Trp)( Figure 3S ).

[0031] Figure 4A-4D Figure 2 is a diagram depicting the structure of the following exemplary peptides: Peptide 224 ( Figure 4A )、peptide 229( Figure 4B )、peptide 188( Figure 4C ) and peptide 195 ( Figure 4D ). DETAILED DESCRIPTION

[0032] I. Definitions

[0033] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present disclosure relates. For example, Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd edition, 2002, CRC Press; Dictionary of Cell and Molecular Biology, 3rd edition, 1999, Academic Press; and Oxford Dictionary Of Biochemistry And Molecular Biology, Revised Edition, 2000, Oxford University Press provide a general dictionary annotation of many of the terms used in the present disclosure to the skilled person.

[0034] Units, prefixes and symbols are expressed in the form accepted by their International System of Units (SI). Numerical ranges include numerical values ​​that limit the range. Unless otherwise indicated, amino acid sequences are written from left to right in the amino to carboxyl direction. The titles provided herein are not limitations of the various aspects of the present disclosure, which can be obtained by reference to this specification as a whole. Therefore, the terms defined below can be more completely defined by reference to the specification as a whole.

[0035] Throughout this disclosure, the term "a" or "an" entity refers to one or more of the entity; for example, "a polynucleotide" is understood to mean one or more polynucleotides. Therefore, the terms "a" (or "a"), "one or more", and "at least one" are used interchangeably herein.

[0036] In addition, "and / or" when used herein is considered to mean that each of the two specified features or components is specifically disclosed together with the other or is not specifically disclosed together with the other. Therefore, the term "and / or" as used in phrases such as "A and / or B" herein is intended to include "A and B", "A or B", "A" (alone) and "B" (alone). Similarly, the term "and / or" as used in phrases such as "A, B and / or C" is intended to cover each of the following aspects: A, B and C; A, B or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).

[0037] As used herein, the terms "about" and "approximately" when used to modify a numerical value or numerical range, represent a deviation of up to 10% above the value or range and up to 10% below the value or range, which is still within the intended meaning of the indicated value or range. It should be understood that wherever an aspect is described herein using the language "about" or "approximately" a numerical value or range, other similar aspects referring to the specific numerical value or range are also provided.

[0038] It should be understood that wherever the language "comprising" is used herein to describe an aspect, other similar aspects described using "consisting of" and / or "consisting essentially of" are also provided. A peptide "comprising" a particular amino acid sequence refers to a peptide containing the amino acid sequence, wherein the peptide may or may not contain additional amino acids or other modifications to the amino acid sequence. A peptide "consisting of a particular amino acid sequence" refers to a peptide containing only the amino acid sequence and no additional amino acids or other modifications to the amino acid sequence. A peptide "comprising" or "consisting of" an amino acid sequence refers to a peptide containing the amino acid sequence and no additional amino acids; however, the peptide may contain other modifications to the amino acid sequence (e.g., an acyl moiety or a palmitoyl moiety).

[0039] As used herein, the term "amino acid" refers to naturally occurring and non-natural amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to naturally occurring amino acids. Naturally encoded amino acids are the 20 common amino acids (alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine) as well as pyrrolysine and selenocysteine. Amino acid analogs refer to compounds that have the same basic chemical structure (i.e., alpha carbon bound to hydrogen, carboxyl, amino, and R groups) as naturally occurring amino acids, such as homoserine, norleucine, methionine sulfoxide, and methionine methylsulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as naturally occurring amino acids.

[0040] "Non-natural amino acid" refers to an amino acid that is not one of the 20 common amino acids or pyrrolysine or selenocysteine; other terms that may be used synonymously with the term "non-natural amino acid" are "non-naturally encoded amino acid," "unnatural amino acid," "non-naturally occurring amino acid," and various hyphenated and non-hyphenated versions thereof. The term "non-natural amino acid" includes, but is not limited to, amino acids that occur naturally by modifying naturally encoded amino acids (including, but not limited to, the 20 common amino acids or pyrrolysine and selenocysteine) but that are not themselves incorporated into a growing polypeptide chain by the translation complex.

[0041] Examples of non-naturally encoded naturally occurring amino acids include, but are not limited to, ((1H-imidazol-4-yl)methyl)glycine (NHis), S, 1-aminocyclobutane-1-carboxylic acid (1-aminocyclobutane-1-carboxylic acid; Acbu), 1-aminocyclopropane-1-carboxylic acid (1-aminocyclopropane-1-carboxylic acid; Acpr), aminoisobutyric acid (2-amino-2-methylpropionic acid; Aib), D-serine (dSer), α-methyl-serine ((S)-2-amino-3-hydroxy-2-methylpropionic acid (αMeSer); αMeSer), methyl-L-glutamine (N-MeGln), α-methyl-glutamine ((S)-2,5-diamino-2-methyl-5-oxopentanoic acid; αMeGln), β-dimethylGln, α-methyl-phenylalanine ((S)-2-amino-2-methyl-3-phenylpropionic acid; αMePhe), acetylated lysine N 6-acetyl-L-lysine (Ac-Lys), diphenylalanine ((S)-2-amino-3,3-diphenylpropionic acid; Dip), β-dimethylarginine ((S)-2-amino-5-guanidino-3,3-dimethylpentanoic acid; β-dimethylArg), β-cyclohexyl-L-alanine ((S)-2-amino-3-cyclohexylpropionic acid; Cha), norleucine ((S)-2-aminohexanoic acid; Nle), D-glutamine (dGln), (S)-3-([1,1'-biphenyl]-4-yl)-2-aminopropionic acid (Bip), 1-methyl-L-tryptophan (1-methyl-Trp), and (S)-2-amino-3-(5-bromo-1H-indol-3-yl)propionic acid (5-Br-Trp).

[0042] Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Likewise, nucleotides may be referred to by their commonly accepted single-letter codes.

[0043] As used herein, the term "polypeptide" is intended to encompass the singular "polypeptide" as well as the plural "polypeptides," and includes any chain or chains of two or more amino acids. Thus, as used herein, "peptide," "peptide subunit," "protein," "amino acid chain," "amino acid sequence," or any other term used to refer to a chain or chains of two or more amino acids, are included in the definition of "polypeptide," although each of these terms may have a more specific meaning. The term "polypeptide" may be used to replace any of these terms or to be used interchangeably with any of these terms. The term also includes polypeptides that undergo post-translational or post-synthetic modifications, such as conjugation of palmitoyl groups, glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting / blocking groups, proteolytic cleavage, or modification by non-naturally occurring amino acids.

[0044] More specifically, the term "peptide" as used herein encompasses full-length peptides as well as fragments, variants or derivatives thereof, such as GLP-1 / glucagon agonist peptides (e.g., 29, 30 or 31 amino acids in length). "Peptides" such as GLP-1 / glucagon agonist peptides disclosed herein may be part of a fusion polypeptide comprising additional components such as an Fc domain or an albumin domain to increase half-life. The peptides described herein may also be derivatized in many different ways. The peptides described herein may comprise modifications including, for example, conjugation of lipids including palmitoyl, stearoyl, lauryl, myristoyl, heptadecanoyl, octadecanedioic acid (C18 diacid) or eicosanedioic acid (C20 diacid). Exemplary lipids are provided at Figure 1A-1G .

[0045] The peptides described herein may comprise modifications including, for example, conjugation of a linker comprising 2-(2-(2-aminoethoxy)ethoxy)acetic acid (O2Oc), PEG and / or gamma glutamic acid (γE). In some aspects, the linker comprises 2-(2-(2-aminoethoxy)ethoxy)acetic acid (O2Oc), (O2Oc)-(O2Oc), (O2Oc)-γE-(O2Oc), 3-(2-(2-aminoethoxy)ethoxy)propionic acid) ((PEG)2), 1-amino-3,6,9,12-tetraoxapentadecan-15-oic acid ((PEG)4), 1-amino-3,6,9,12,15,18,21,14-octaoxaheptacosanoic acid ((PEG)8), 1-amino-3,6,9,12,15,18,21,24,27,30,33,36-dodecanoic acid ((PEG)12), γ-glutamic acid (γE), (PEG)2-(PEG)2-γE-γE, (PEG)2- EG)2-γE-(PEG)2-γE, γE-(O2Oc), γE-(O2Oc)-(O2Oc), γE-(O2Oc)-γE-(O2Oc), γE- (PEG)2-(PEG)2, γE-(PEG)2-γE-(PEG)2, γE-(PEG)4, γE-γE, γE-γE-(O2Oc), γE-γE -(O2Oc)-(O2Oc), γE-γE-(PEG)12, γE-γE-(PEG)2-(PEG)2, γE-γE-(PEG)2-γE-γE, γE-γE-(PEG)4, γE-γE-(PEG)8, γE-γE-(O2Oc)-(O2Oc)-γE-γE and (PEG)2-(PEG)2-γE. Exemplary connectors are provided at Figure 2A-2V .

[0046] The term "isolated" refers to a state in which a peptide or nucleic acid will generally be in accordance with the present disclosure. Isolated peptides and isolated nucleic acids will be free of or substantially free of the materials with which they are naturally associated, such as other peptides or nucleic acids with which they are found in their natural environment, or in the environment in which they are prepared (e.g., cell culture) when such preparation is by recombinant DNA techniques implemented in vitro or in vivo. The peptides and nucleic acids can be formulated with diluents or adjuvants and still be separated for practical purposes - for example, if the peptides are used to coat microtiter plates for immunoassays, the peptides will generally be mixed with gelatin or other carriers, or when used in diagnosis or therapy, will be mixed with pharmaceutically acceptable carriers or diluents.

[0047] A "recombinant" peptide refers to a peptide produced via recombinant DNA technology. For the purposes of this disclosure, a recombinantly produced peptide expressed in a host cell is also considered isolated, as are native or recombinant polypeptides that are separated, fractionated, or partially or substantially purified by any suitable technique.

[0048] When referring to GLP-1 / glucagon agonist peptides, the terms "fragment", "analog", "derivative" or "variant" include any peptide that retains at least some desired activity (e.g., binding to a glucagon receptor and / or a GLP-1 receptor). Fragments of the GLP-1 / glucagon agonist peptides provided herein include proteolytic fragments, deletion fragments that exhibit desired properties during expression, purification and / or administration to a subject.

[0049] As used herein, the term "variant" refers to a peptide that is different from the peptide shown due to amino acid substitution, deletion, insertion and / or modification. Variants can be produced using mutagenesis techniques known in the art. Variants may also or alternatively contain other modifications. For example, the peptide can be conjugated or coupled, such as fused to a heterologous amino acid sequence or other portion, such as for increasing half-life, solubility or stability. Examples of portions to be conjugated or coupled to the peptides provided herein include, but are not limited to, albumin, immunoglobulin Fc regions, polyethylene glycol (PEG), and the like. The peptide can also be conjugated or coupled to a linker or other sequence to facilitate synthesis, purification or identification of the peptide (e.g., 6-His) or to enhance binding of the polypeptide to a solid support.

[0050] The term "composition" or "pharmaceutical composition" refers to a composition containing a GLP-1 / glucagon agonist peptide provided herein together with, for example, a pharmaceutically acceptable carrier, excipient or diluent for administration to a subject in need of treatment, such as a human subject in need of improved glycemic control, weight loss, treatment of type 2 diabetes, and / or treatment of NASH.

[0051] The term "pharmaceutically acceptable" refers to compositions that are, within the scope of sound medical judgment, suitable for contact with the tissues of humans and animals without excessive toxicity or other complications, commensurate with a reasonable benefit / risk ratio.

[0052] An "effective amount" is an amount of an agent provided herein (e.g., GLP-1 / glucagon agonist peptide) that, when administered to a subject in a single dose or as part of a series of doses, is effective for treatment, e.g., for improving glycemic control, reducing weight, treating type 2 diabetes, and / or treating NASH.

[0053] As used herein, the terms "subject" and "patient" are used interchangeably. The subject can be an animal. In some aspects of the present disclosure, the subject is a mammal, such as a non-human animal (e.g., a cow, a pig, a horse, a cat, a dog, a rat, a mouse, a monkey or other primate, etc.). In some aspects of the present disclosure, the subject is a cynomolgus macaque. In some aspects of the present disclosure, the subject is a human.

[0054] As used herein, a "subject in need thereof" or "patient in need thereof" refers to an individual for whom treatment is desirable, such as a subject in need of improved glycemic control, weight loss, treatment of type 2 diabetes, and / or treatment of NASH.

[0055] Terms such as "treating," "treatment," or "to treat" refer to therapeutic measures that cure a confirmed pathological condition or disorder and / or prevent the progression of a confirmed pathological condition or disorder. Terms such as "prevention" refer to prophylactic or preventative measures that prevent and / or slow the development of a targeted pathological condition or disorder. Thus, those in need of treatment include those already suffering from the disease or condition. Those in need of prevention include those susceptible to the disease or condition as well as those in which the disease or condition is to be prevented.

[0056] Terms such as "reducing severity" refer to therapeutic measures that alleviate or lessen the symptoms of an established pathological condition or disorder.

[0057] As used herein, a "GLP-1 agonist peptide" is a peptide that is not native GLP-1 but exhibits about at least 1% or more activity at the GLP-1 receptor relative to native GLP-1 under the conditions of a cAMP assay (see Example 2). In some aspects, the GLP-1 agonist peptide exhibits at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more activity at the GLP-1 receptor relative to native GLP-1 under the conditions of a cAMP assay (see Example 2).

[0058] As used herein, a "glucagon agonist peptide" is a peptide that is not native glucagon but exhibits at least 1% or more activity at the glucagon receptor relative to native glucagon under conditions of a cAMP assay (see Example 2). In some aspects, a glucagon agonist peptide exhibits at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more activity at the glucagon receptor relative to native GLP-1 under conditions of a cAMP assay (see Example 2).

[0059] As used herein, a "GLP-1 / glucagon agonist peptide", "GLP-1 / glucagon co-agonist peptide", "GLP-1 and glucagon dual agonist peptide" or "GLP-1 and glucagon dual co-agonist peptide" is a peptide that is not native GLP-1 and is not native glucagon, and that exhibits at least 1% or more of the activity at the glucagon receptor relative to native glucagon under the conditions of the cAMP assay (see Example 2), and also exhibits about at least 1% or more of the activity at the GLP-1 receptor relative to native GLP-1. In some aspects, the "GLP-1 / glucagon agonist peptide" or "GLP-1 and glucagon dual agonist peptide" exhibits at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more activity at the glucagon receptor relative to native glucagon under the conditions of the cAMP assay (see Example 2), and also exhibits about at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more activity at the GLP-1 receptor relative to native GLP-1.

[0060] As used herein, the term "relative potency ratio" refers to %GLP-1R activity relative to GLP-1 / %GlucR activity relative to glucagon.

[0061] As used herein, the term "native glucagon" refers to naturally occurring glucagon, such as human glucagon, comprising the sequence of SEQ ID NO: 1. The term "native GLP-1" refers to naturally occurring GLP-1, such as human GLP-1, and is a general term covering, for example, GLP-1 (7-36) amide (SEQ ID NO: 2), GLP-1 (7-37) acid (SEQ ID NO: 3), or a mixture of those two compounds. As used herein, in the absence of any further designation, general references to "glucagon" or "GLP-1" are intended to mean native human glucagon or native human GLP-1, respectively. Unless otherwise indicated, "glucagon" refers to human glucagon, and "GLP-1" refers to human GLP-1.

[0062] As used herein, the term "sequence identity" refers to the relationship between two or more polynucleotide sequences or between two or more polypeptide sequences. When a position in a sequence is occupied by the same nucleic acid base or amino acid in the corresponding position of the comparison sequence, the sequence is referred to as being "consistent" at that position. Percentage "sequence identity" is calculated by determining the number of positions at which consistent nucleic acid bases or amino acids appear in the two sequences to obtain the number of "consistent" positions. The number of "consistent" positions is then divided by the total number of positions in the comparison window and multiplied by 100 to obtain the percentage of "sequence identity". The percentage of "sequence identity" is determined by comparing two optimally aligned sequences on the comparison window. In order to optimally align the sequence for comparison, the part of the polynucleotide or polypeptide sequence in the comparison window can include an addition or deletion referred to as a gap, while the reference sequence remains unchanged. The best alignment is such an alignment that, even with a gap, can produce the maximum possible number of "consistent" positions between the reference and comparison sequences. The percentage "sequence identity" between two sequences can be determined using the version of the program "BLAST 2 sequences" available from the National Center for Biotechnology Information as of September 1, 2004, which can be used in conjunction with the programs BLASTN (for nucleotide sequence comparisons) and BLASTP (for polypeptide sequence comparisons), which are based on the algorithm of Karlin and Altschul (Proc. Natl. Acad. Sci. USA 90(12):5873-5877, 1993). When using "BLAST 2 sequences", the parameters that are the default parameters as of September 1, 2004 can be used for the following: word length (3), open gap penalty (11), extension gap penalty (1), gap drop-off (50), expectation (10), and any other desired parameters including, but not limited to, matrix options.

[0063] Glucagon (SEQ ID NO: 1)

[0064] HSQGTFTSDYSKYLDSRRAQDFVQWLMNT-Acid

[0065] GLP-1 (7-36) amide (SEQ ID NO: 2)

[0066] HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-amide

[0067] GLP-1(7-37) acid (SEQ ID NO:3)

[0068] HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG-Acid

[0069] II. GLP-1 / Glucagon Agonist Peptide

[0070] Provided herein are peptides that are combined with the glucagon receptor and the GLP-1 receptor. In some aspects, provided herein are peptides that are co-agonists (dual agonists) of glucagon and GLP-1 activity. Such peptides are referred to herein as GLP-1 / glucagon agonist peptides. In some aspects, as provided herein, GLP-1 / glucagon agonist peptides are active at human GLP1 and human glucagon receptors.

[0071] In certain aspects, the GLP-1 / glucagon agonist peptides provided herein exhibit an in vitro potency at the GLP-1 receptor of less than 10,000 pM, less than 5000 pM, less than 2500 pM, less than 1000 pM, less than 900 pM, less than 800 pM, less than 700 pM, less than 600 pM, less than 500 pM, less than 400 pM, less than 300 pM, less than 200 pM, less than 100 pM, less than 50 pM, less than 25 pM, less than 20 pM, less than 15 pM, less than 10 pM, less than 5 pM, less than 4 pM, less than 3 pM or less than 2 pM as shown by EC50 in a cAMP assay (see Example 2).

[0072] In certain aspects, the GLP-1 / glucagon agonist peptides provided herein exhibit an in vitro potency at the glucagon receptor of less than 10,000 pM, less than 5000 pM, less than 2500 pM, less than 1000 pM, less than 900 pM, less than 800 pM, less than 700 pM, less than 600 pM, less than 500 pM, less than 400 pM, less than 300 pM, less than 200 pM, less than 100 pM, less than 50 pM, less than 25 pM, less than 20 pM, less than 15 pM, less than 10 pM, less than 5 pM, less than 4 pM, less than 3 pM or less than 2 pM as shown by EC50 in a cAMP assay (see Example 2).

[0073] In certain aspects, the GLP-1 / glucagon agonist peptides provided herein have a hGLP-1R / hGCGR relative potency ratio of about 1 to about 25. In certain aspects, the GLP-1 / glucagon agonist peptides provided herein have a hGLP-1R / hGCGR relative potency ratio of about 1 to about 20. In certain aspects, the GLP-1 / glucagon agonist peptides provided herein have a hGLP-1R / hGCGR relative potency ratio of about 1 to about 15. In certain aspects, the GLP-1 / glucagon agonist peptides provided herein have a hGLP-1R / hGCGR relative potency ratio of about 1 to about 10.

[0074] In certain aspects, the GLP-1 / glucagon agonist peptides provided herein have a hGLP-1R / hGCGR relative potency ratio of about 2 to about 25. In certain aspects, the GLP-1 / glucagon agonist peptides provided herein have a hGLP-1R / hGCGR relative potency ratio of about 2 to about 20. In certain aspects, the GLP-1 / glucagon agonist peptides provided herein have a hGLP-1R / hGCGR relative potency ratio of about 2 to about 15. In certain aspects, the GLP-1 / glucagon agonist peptides provided herein have a hGLP-1R / hGCGR relative potency ratio of about 2 to about 10.

[0075] In certain aspects, the GLP-1 / glucagon agonist peptides provided herein, when administered to mice at 10 nmol / kg (as performed in Example 3), reduce 24-hour food intake relative to mice treated with vehicle controls by at least 10%. In certain aspects, the GLP-1 / glucagon agonist peptides provided herein, when administered to mice at 10 nmol / kg (as performed in Example 3), reduce 24-hour food intake relative to mice treated with vehicle controls by at least 20%. In certain aspects, the GLP-1 / glucagon agonist peptides provided herein, when administered to mice at 10 nmol / kg (as performed in Example 3), reduce 24-hour food intake relative to mice treated with vehicle controls by at least 30%.

[0076] In some aspects, the GLP-1 / glucagon agonist peptides provided herein, when administered to mice at 10 nmol / kg (as performed in Example 3), reduce 24-hour food intake by 10%-70% relative to mice treated with vehicle controls. In some aspects, the GLP-1 / glucagon agonist peptides provided herein, when administered to mice at 10 nmol / kg (as performed in Example 3), reduce 24-hour food intake by at least 20% or 20%-70% relative to mice treated with vehicle controls. In some aspects, the GLP-1 / glucagon agonist peptides provided herein, when administered to mice at 10 nmol / kg (as performed in Example 3), reduce 24-hour food intake by at least 30% or 30%-70% relative to mice treated with vehicle controls.

[0077] In some aspects, the GLP-1 / glucagon agonist peptides provided herein are stable. For example, in some aspects, the GLP-1 / glucagon agonist peptides provided herein are stable in the presence of FasSSGF (fasted state simulated gastric fluid), such that at least 25% of the GLP-1 / glucagon agonist peptides remain intact after incubation with FasSSGF for 30 minutes (as performed in Example 4). In some aspects, the GLP-1 / glucagon agonist peptides provided herein are stable in the presence of FasSSGF, such that at least 40% of the GLP-1 / glucagon agonist peptides remain intact after incubation with FasSSGF for 30 minutes (as performed in Example 4). In some aspects, the GLP-1 / glucagon agonist peptides provided herein are stable in the presence of FasSSGF, such that at least 50% of the GLP-1 / glucagon agonist peptides remain intact after incubation with FasSSGF for 30 minutes (as performed in Example 4). In certain aspects, the GLP-1 / glucagon agonist peptides provided herein are stable in the presence of FasSSGF, such that at least 60% of the GLP-1 / glucagon agonist peptide remains intact after incubation with FasSSGF for 30 minutes (as performed in Example 4). In certain aspects, the GLP-1 / glucagon agonist peptides provided herein are stable in the presence of FasSSGF, such that at least 70% of the GLP-1 / glucagon agonist peptide remains intact after incubation with FasSSGF for 30 minutes (as performed in Example 4).

[0078] In certain aspects, the GLP-1 / glucagon agonist peptides provided herein are stable in the presence of enkephalinase, such that at least 55% of the GLP-1 / glucagon agonist peptides remain intact after 24 hours of incubation with enkephalinase (as performed in Example 5). In certain aspects, the GLP-1 / glucagon agonist peptides provided herein are stable in the presence of enkephalinase, such that at least 60% of the GLP-1 / glucagon agonist peptides remain intact after 24 hours of incubation with enkephalinase (as performed in Example 5). In certain aspects, the GLP-1 / glucagon agonist peptides provided herein are stable in the presence of enkephalinase, such that at least 65% of the GLP-1 / glucagon agonist peptides remain intact after 24 hours of incubation with enkephalinase (as performed in Example 5). In certain aspects, the GLP-1 / glucagon agonist peptides provided herein are stable in the presence of enkephalinase, such that at least 70% of the GLP-1 / glucagon agonist peptides remain intact after 24 hours of incubation with enkephalinase (as performed in Example 5). In certain aspects, the GLP-1 / glucagon agonist peptides provided herein are stable in the presence of enkephalinase, such that at least 75% of the GLP-1 / glucagon agonist peptides remain intact after 24 hours of incubation with enkephalinase (as performed in Example 5). In certain aspects, the GLP-1 / glucagon agonist peptides provided herein are stable in the presence of enkephalinase, such that at least 80% of the GLP-1 / glucagon agonist peptides remain intact after 24 hours of incubation with enkephalinase (as performed in Example 5). In certain aspects, the GLP-1 / glucagon agonist peptides provided herein are stable in the presence of enkephalinase, such that at least 85% of the GLP-1 / glucagon agonist peptides remain intact after incubation with enkephalinase for 24 hours (as performed in Example 5). In certain aspects, the GLP-1 / glucagon agonist peptides provided herein are stable in the presence of enkephalinase, such that at least 90% of the GLP-1 / glucagon agonist peptides remain intact after incubation with enkephalinase for 24 hours (as performed in Example 5). In certain aspects, the GLP-1 / glucagon agonist peptides provided herein are stable in the presence of enkephalinase, such that at least 95% of the GLP-1 / glucagon agonist peptides remain intact after incubation with enkephalinase for 24 hours (as performed in Example 5).

[0079] In some aspects, the GLP-1 / glucagon agonist peptides provided herein are stable. For example, in some aspects, the GLP-1 / glucagon agonist peptides provided herein are stable in the presence of FasSSIF (fasted state simulated intestinal fluid) / pancreatin, so that at least 10% of the GLP-1 / glucagon agonist peptides remain intact after incubation with FasSSIF / pancreatin for 30 minutes (as performed in Example 6). In some aspects, the GLP-1 / glucagon agonist peptides provided herein are stable. For example, in some aspects, the GLP-1 / glucagon agonist peptides provided herein are stable in the presence of FasSSIF / pancreatin, so that at least 20% of the GLP-1 / glucagon agonist peptides remain intact after incubation with FasSSIF / pancreatin for 30 minutes (as performed in Example 6). In some aspects, the GLP-1 / glucagon agonist peptides provided herein are stable. For example, in some aspects, the GLP-1 / glucagon agonist peptides provided herein are stable in the presence of FasSSIF / pancreatin, such that at least 25% of the GLP-1 / glucagon agonist peptides remain intact after incubation with FasSSIF / pancreatin for 30 minutes (as performed in Example 6). In some aspects, the GLP-1 / glucagon agonist peptides provided herein are stable. For example, in some aspects, the GLP-1 / glucagon agonist peptides provided herein are stable in the presence of FaSSSIF / pancreatin, such that at least 50% of the GLP-1 / glucagon agonist peptides remain intact after incubation with FasSSSIF / pancreatin for 30 minutes (as performed in Example 6). In some aspects, the GLP-1 / glucagon agonist peptides provided herein are stable. For example, in some aspects, the GLP-1 / glucagon agonist peptides provided herein are stable in the presence of FasSSIF / pancreatin, such that at least 75% of the GLP-1 / glucagon agonist peptides remain intact after incubation with FasSSIF / pancreatin for 30 minutes (as performed in Example 6). In some aspects, the GLP-1 / glucagon agonist peptides provided herein are stable. For example, in some aspects, the GLP-1 / glucagon agonist peptides provided herein are stable in the presence of FasSSIF / pancreatin, such that at least 80% of the GLP-1 / glucagon agonist peptides remain intact after incubation with FasSSIF / pancreatin for 30 minutes (as performed in Example 6). In some aspects, the GLP-1 / glucagon agonist peptides provided herein are stable. For example, in certain aspects, the GLP-1 / glucagon agonist peptides provided herein are stable in the presence of FasSSIF / pancreatin, such that at least 90% of the GLP-1 / glucagon agonist peptide remains intact after 30 minutes of incubation with FasSSIF / pancreatin (as performed in Example 6).

[0080] The GLP-1 / glucagon agonist peptides disclosed herein may comprise heterologous moieties, for example to extend half-life. The heterologous moieties may be proteins, peptides, protein domains, linkers, organic polymers, inorganic polymers, polyethylene glycol (PEG), biotin, albumin, human serum albumin (HSA), HSA FcRn binding moieties, antibodies, antibody domains, antibody fragments, single chain antibodies, domain antibodies, albumin binding domains, enzymes, ligands, receptors, binding peptides, non-FnIII scaffolds, epitope tags, recombinant polypeptide polymers, cytokines, and combinations of two or more of such moieties.

[0081] In some aspects, the GLP-1 / glucagon agonist peptides disclosed herein bind to the GLP-1 receptor (GLP-1R), to the glucagon receptor (GCGR), or to both the GLP-1R and GCGR. In some aspects, the GLP-1R is human GLP-1R. In some aspects, the GCGR is human GCGR. In some aspects, the peptide is an agonist of GLP-1 activity, an agonist of glucagon activity, or an agonist of both GLP-1 and glucagon activity.

[0082] In some aspects, the GLP-1 / glucagon agonist peptides as disclosed herein have increased resistance to proteolysis relative to the natural ligands of GLP-1R and / or GCGR. In some aspects, the GLP-1 / glucagon agonist peptides as disclosed herein have increased resistance to proteolysis relative to codul peptide (SEQ ID NO: 358). In some aspects, the GLP-1 / glucagon agonist peptides as disclosed herein have increased resistance to proteolysis relative to semaglutide (SEQ ID NO: 359). In some aspects, the GLP-1 / glucagon agonist peptides as disclosed herein have increased resistance to proteolysis relative to codul peptide (SEQ ID NO: 358) and semaglutide (SEQ ID NO: 359).

[0083] In some aspects, the GLP-1 / glucagon agonist peptides provided herein comprise the sequence: X1-X2-X3-G-X5-X6-TSD-X10-S-X12-X13-L-X15-X16-X17-X18-X19-X20-X21-X22-X23-X24-X25-X26-X27-X28-X29-X30-X31-Z, wherein X1 is H or NHis, X2 is S, 1-aminocyclobutane-1-carboxylic acid (Acbu), 1-aminocyclopropane-1-carboxylic acid (Acpr), aminoisobutyric acid (Aib), D-serine (dSer), or α-methyl-serine (αMeS). er), X3 is Q, H, I, D-glutamine (dGln), methyl-L-glutamine (N-MeGln), α-methyl-glutamine (αMeGln) or β-dimethylglutamine (β-dimethylGln), X5 is T or S, X6 is F or α-methyl-phenylalanine (αMePhe), X10 is Y, K or V, wherein K may contain an acyl moiety and / or may be lipidated, X12 is K, acetylated lysine (Ac-Lys), E or R, X13 is Y, Aib, α-methyl-phenylalanine (αMePhe), diphenylalanine (Dip), I or K, wherein K may contain an acyl moiety and / or may be lipidated , X15 is D or E, X16 is S, Aib, E, T, R, A, K, L or V, X17 is R, E, K, Q or β-dimethylarginine (β-dimethylArg), wherein K may contain an acyl moiety and / or may be lipidated, X18 is R, A, Aib, Q, S or β-dimethylArg, X19 is A or V, X20 is Q, Aib, E, K, L or R, wherein K may contain an acyl moiety and / or may be lipidated, X21 is D, E or L, X22 is F, I or αMePhe, X23 is V or I, X24 is Q, A, E, K, L or R, wherein K may contain an acyl moiety and / or may be lipidated, X2 wherein the peptide does not comprise SEQ ID NO: 1 and does not comprise HSQGTFTSDX10SEYLDSERARDFVAWLEAGG-acid,wherein X10 = Lys[ε-γE-palmitoyl] (SEQ ID NO: 538). In some aspects, X2 is Aib and / or X10 is V. In some aspects, X3 is Q, X15 is D, X18 is R, X20 is R, X21 is D, X23 is V, and / or X30 is G. In some aspects, X13 is αMePhe, X16 is T, X17 is K, X27 is L, X28 is E, and / or X29 is Aib. ,

[0084] In some aspects, the residue at position 10, 13, 17, 20 or 24 is acylated. In some aspects, the residue at position 10, 13, 17, 20 or 24 is lipidated. In some aspects, the lipid is selected from palmitoyl, stearoyl, lauryl, myristoyl, heptadecanoyl, arachidoyl, octadecanedioic acid (C18 diacid) and eicosanedioic acid (C20 diacid).

[0085] In some aspects, the lipid attached to the residue at position 10, 13, 17, 20, or 24 is attached via a linker. In some aspects, the linker is selected from (O2Oc), (O2Oc)-(O2Oc), (O2Oc)-γE-(O2Oc), (PEG)2-(PEG)2-γE-γE, (PEG)2-γE-(PEG)2-γE, γE, γE-(O2Oc), γE-(O2Oc)-(O2Oc), γE-(O2Oc)-γE-(O2Oc), γE-(PEG)2-γE-(PEG)2 2. γE-(PEG)4, γE-γE, γE-γE-(O2Oc), γE-γE-(O2Oc)-(O2Oc), γE-γE-(PEG)12, γE-γE-(PEG)2-(PEG)2, γ E-γE-(PEG)2-γE-γE, γE-γE-(PEG)4, (PEG)2-(PEG)2-γE, γE-γE-(O2Oc)-(O2Oc)-γE-γE and γE-γE-(PEG)8.

[0086] In some aspects, the linker is attached to the epsilon amino group of the residue at position 10, 13, 17, 20, and / or 24.

[0087] In some aspects, the peptide comprises any one of SEQ ID NOs: 6-411 and 418-537. In some aspects, the peptide comprises SEQ ID NO: 99. In some aspects, the peptide comprises SEQ ID NO: 106. In some aspects, the peptide comprises SEQ ID NO: 228. In some aspects, the peptide comprises SEQ ID NO: 233.

[0088] In some aspects, the peptide comprises the sequence: H-X2-X3-G-X5-X6-TSD-X10-S-X12-X13-L-X15-X16-X17-X18-A-X20-D-X22-X23-X24-X25-X26-X27-X28-X29-X30-X31-Z, wherein X2 is S, aminoisobutyric acid (Aib) or α-methyl-serine (αMeSer), X3 is Q or H, X5 is T or S, X6 is F or α-methyl-phenylalanine (αMePhe), X10 is Y or V, X12 is K or acetylated lysine (Ac-Lys), X13 is Y, αMePhe, Aib, diphenylalanine (Dip) or I, X15 is D or E, X16 is S, T, A, E, K, L, R or V, and X17 is R or K, wherein K may contain an acyl moiety and / or may be lipidated , X18 is R, A, Q or β-dimethylarginine (β-dimethylArg), X20 is Q, R, Aib, L or E, X22 is F, I or αMePhe, X23 is V or I, X24 is Q, E, A, L or R, X25 is W, Aib, S, Dip, I, H, biphenyl-alanine (Bip), 1-methyltryptophan (1-methyl-Trp), 5-bromotryptophan (5-BrTrp) or α MePhe, X26 is L, I or β-cyclohexyl-L-alanine (Cha) or V, X27 is M, A, L, E, V, I, K, norleucine (Nle) or S, X28 is N, Aib, E, (PEG)4, A, S or G, X29 is T, absent, Aib, G, A, R or E, X30 is absent, G, A, Aib, K or E, X31 is absent, and Z is an amide or an acid (SEQ ID NO:5), wherein the peptide does not comprise SEQ ID NO:1.

[0089] In some aspects, the residue at position 17 is acylated. In some aspects, the residue at position 17 is lipidated. In some aspects, the lipid is selected from palmitoyl, stearoyl, lauryl, myristoyl, heptadecanoyl, arachidoyl, octadecanedioic acid (C18 diacid), and eicosanedioic acid (C20 diacid).

[0090] In some aspects, the lipid attached to the residue at position 17 is attached via a linker. In some aspects, the linker is selected from (O2Oc), (O2Oc)-(O2Oc), (O2Oc)-γE-(O2Oc), (PEG)2-(PEG)2-γE-γE, (PEG)2-γE-(PEG)2-γE, γE, γE-(O2Oc), γE-(O2Oc)-(O2Oc), γE-(O2Oc)-γE-(O2Oc), γE-(PEG)2-(PEG)2-γE G)2, γE-(PEG)2-γE-(PEG)2, γE-(PEG)4, γE-γE, γE-γE-(O2Oc), γE-γE-(O2Oc)-(O2Oc), γE- γE-(PEG)12, γE-γE-(PEG)2-(PEG)2, γE-γE-(PEG)2-γE-γE, γE-γE-(PEG)4 and γE-γE-(PEG)8. In some aspects, the linker is selected from γE-γE-(O2Oc)-(O2Oc)-γE-γE, (O2Oc)-(O2Oc), γE, γE-(O2Oc)- (O2Oc), γE-γE-(O2Oc)-(O2Oc), γE-γE-(PEG)4, γE-γE-(PEG)2-(PEG)2, γE-γ E-(PEG)8, γE-γE-(PEG)12, (PEG)2-(PEG)2-γE-γE, (PEG)2-γE-(PEG)2-γE, γE-(PEG)2-γE-(PEG)2, γE-(PEG)2-(PEG)2, (PEG)2-(PEG)2-γE and γE-(PEG)4.

[0091] In some aspects, the linker is attached to the epsilon amino group of the residue at position 17.

[0092] In some aspects, the peptide comprises the sequence: H-aminoisobutyric acid (Aib)-QGT-X6-TSDVSK-αmethyl-phenylalanine (αMePhe)-L-X15-X16-K-X18-A-X20-X21-X22-X23-X24-W-X26-X27-X28-X29-X30-X31-Z, wherein X6 is F or αmethyl-phenylalanine (αMePhe), X15 is E or D, X16 is T, S, K, E, A, L or R, X18 is R or A, X20 is R, Q or L, X21 is D or E, and X22 is F or αMePhe, X23 is V or I, X24 is R, A, Q or L, X25 is W, αMePhe biphenyl-alanine (Bip), 1-methyltryptophan (1-methyl-Trp), 5-bromotryptophan (5-BrTrp) or Aib, X26 is L, I or V, X27 is L, A, E, V, I or K, X28 is E, S, A, Aib, absent or R, X29 is G, Aib, R, T, E, A or absent, X30 is G, Aib, E, A, K or absent, X31 is I or absent and or G, and Z is an amide or an acid (SEQ ID NO: 412).

[0093] In some aspects, the lysine at position 17 is acylated. In some aspects, the lysine at position 17 is esterified. In some aspects, the lipid is selected from palmitoyl, stearoyl, lauryl, myristoyl, heptadecanoyl, arachidoyl, octadecanedioic acid (C18 diacid) and eicosanedioic acid (C20 diacid). In some aspects, the lipid is selected from octadecanedioic acid (C18 diacid) and eicosanedioic acid (C20 diacid). In some aspects, the lipid is octadecanedioic acid (C18 diacid). In some aspects, the lipid is eicosanedioic acid (C20 diacid).

[0094] In some aspects, the lipid is linked to the lysine at position 17 via a linker. In some aspects, the linker is selected from (O2Oc), (O2Oc)-(O2Oc), (O2Oc)-γE-(O2Oc), (PEG)2-(PEG)2-γE-γE, (PEG)2-γE-(PEG)2-γE, γE, γE-(O2Oc), γE-(O2Oc)-(O2Oc), γE-(O2Oc)-γE-(O2Oc), γE-(PEG)2-γE-( PEG)2, γE-(PEG)4, γE-γE, γE-γE-(O2Oc), γE-γE-(O2Oc)-(O2Oc), γE-γE-(PEG)12, γE-γE-(PEG)2-(PE G)2, γE-γE-(PEG)2-γE-γE, γE-γE-(PEG)4, PEG)2-(PEG)2-γE, γE-γE-(O2Oc)-(O2Oc) and γE-γE-(PEG)8. In some aspects, the peptide of claim X, wherein the linker is selected from (PEG)2-(PEG)2-γE, (O2Oc)-(O2Oc), γE, γE-(O2Oc)-(O2Oc), γE-γE-(O2Oc)-(O2Oc), and γE-γE(O2Oc)-(O2Oc)-γE-γE. In some aspects, the linker is γE-(O2Oc)-(O2Oc).

[0095] In some aspects, the linker is attached to the epsilon amino group of the residue at position 17.

[0096] In certain aspects, the GLP-1 / glucagon agonist peptides as disclosed have desirable potency at the glucagon receptor and the GLP-1 receptor, and have desirable relative potency for promoting weight loss.

[0097] In some aspects, the peptide has a sequence of any one of SEQ ID NOs: 6-206 and 418-531. In some aspects, the peptide comprises SEQ ID NO: 99. In some aspects, the peptide comprises SEQ ID NO: 106.

[0098] In some aspects, the peptide has Figure 4C-4D In some aspects, the peptide has Figure 4C In some aspects, the peptide has Figure 4D structure.

[0099] In some aspects, the peptide is any one of the peptides in Table 1.

[0100] Table 1. Peptides modified at position 17

[0101]

[0102]

[0103]

[0104]

[0105]

[0106]

[0107]

[0108]

[0109]

[0110]

[0111]

[0112]

[0113]

[0114]

[0115]

[0116]

[0117]

[0118]

[0119]

[0120]

[0121]

[0122]

[0123]

[0124]

[0125]

[0126]

[0127]

[0128]

[0129]

[0130]

[0131]

[0132]

[0133]

[0134]

[0135]

[0136]

[0137]

[0138]

[0139]

[0140]

[0141]

[0142]

[0143]

[0144]

[0145]

[0146]

[0147]

[0148]

[0149]

[0150]

[0151]

[0152]

[0153]

[0154]

[0155]

[0156]

[0157]

[0158]

[0159]

[0160]

[0161]

[0162]

[0163]

[0164]

[0165] In some aspects, the peptide comprises the sequence: H-X2-X3-G-X5-X6-TSD-X10-S-X12-X13-L-X15-X16-X17-X18-X19-X20-X21-X22-X23-X24-X25-X26-X27-X28-X29-X30-X31-Z, wherein X2 is S, aminoisobutyric acid (Aib), α-methyl-serine ( αMeS), D-serine (dSer), 1-aminocyclopropane-1-carboxylic acid (Acpr) or S, 1-aminocyclobutane-1-carboxylic acid (Acbu), X3 is Q, H, α-methyl-glutamine (αMeGln), N-methyl-glutamine (N-MeGln), D-glutamine (dGln) or β-dimethylglutamine (β-dimethylGln), X5 is T or S, and X6 is F or α Methyl-phenylalanine (αMePhe), X10 is Y or V, X12 is K, E or R, X13 is Y, αMePhe or Aib, X15 is D or E, X16 is S, T, E or Aib, X17 is R, Q or E, X18 is R, A, Aib or S, X19 is A or V, X20 is Q or K, wherein K may contain an acyl moiety and / or may be lipidated, X21 is D or L, and X22 is F or α-methyl-phenylalanine (αMePhe), X23 is V or I, X24 is Q, E, A or R, X25 is W, Aib or S, X26 is L or I, X27 is M, A, L, E, I or V, X28 is N, E, (PEG)4, Aib, S or A, X29 is T, absent, E or G, X30 is absent, E, T or G, X31 is absent or G, and Z is an amide or an acid (SEQ ID NO:413), wherein the peptide does not comprise SEQ ID NO:1.

[0166] In some aspects, the residue at position 20 is acylated. In some aspects, the residue at position 20 is lipidated. In some aspects, the lipid is selected from palmitoyl, stearoyl, lauryl, myristoyl, heptadecanoyl, octadecanedioic acid (C18 diacid) and eicosanedioic acid (C20 diacid). In some aspects, the lipid is selected from stearoyl, octadecanedioic acid (C18 diacid) and eicosanedioic acid (C20 diacid).

[0167] In some aspects, the lipid attached to the residue at position 20 is attached via a linker. In some aspects, the linker is selected from (O2Oc), (O2Oc)-(O2Oc), (O2Oc)-γE-(O2Oc), (PEG)2-(PEG)2-γE-γE, (PEG)2-γE-(PEG)2-γE, γE, γE-(O2Oc), γE-(O2Oc)-(O2Oc), γE-(O2Oc)-γE-(O2Oc), γE-(PEG)2-(PEG)2-γE G)2, γE-(PEG)2-γE-(PEG)2, γE-(PEG)4, γE-γE, γE-γE-(O2Oc), γE-γE-(O2Oc)-(O2Oc), γE- γE-(PEG)12, γE-γE-(PEG)2-(PEG)2, γE-γE-(PEG)2-γE-γE, γE-γE-(PEG)4 and γE-γE-(PEG)8. In some aspects, the linker is selected from γE, γE-γE, γE-γE-(O2Oc), γE-(O2Oc)-(O2Oc), γE-γE-(O2Oc)-(O2Oc), γE-(O2Oc), γE-γE-(PEG) 2-(PEG)2, γE-(O2Oc)-γE-(O2Oc), γE-(PEG)4, γE-γE-(PEG)4, (O2Oc)-γE-(O2Oc), (O2Oc)-(O2Oc) and (O2Oc).

[0168] In some aspects, the peptide comprises the sequence: H-aminoisobutyric acid (Aib)-QGTFTSD-X10-S-X12-αmethyl-phenylalanine (αMePhe)-LD-X16-X17-X18-AKDFV-X24-W-X26-X27-X28-X29-X30-Z, wherein X10 is V or Y, X12 is K or E, X16 is S or Aib, X17 is R or E, X18 is R or A, X24 is A, R or Q, X26 is L or I, X27 is E, L, A or I, X28 is A, E, Aib, S or N, X29 is G, Aib, T or E, X30 is G, E, T or absent, and Z is an amide or acid (SEQ ID NO: 414).

[0169] In some aspects, the lysine at position 20 is acylated. In some aspects, the lysine at position 20 is lipidated. In some aspects, the lipid is selected from palmitoyl, stearoyl, lauryl, myristoyl, heptadecanoyl, octadecanedioic acid (C18 diacid) and eicosanedioic acid (C20 diacid). In some aspects, the lipid is octadecanedioic acid (C18 diacid).

[0170] In some aspects, the lipid is linked to the lysine at position 20 via a linker. In some aspects, the linker is selected from (O2Oc), (O2Oc)-(O2Oc), (O2Oc)-γE-(O2Oc), (PEG)2-(PEG)2-γE-γE, (PEG)2-γE-(PEG)2-γE, γE, γE-(O2Oc), γE-(O2Oc)-(O2Oc), γE-(O2Oc)-γE-(O2Oc), γE-(PEG)2-(PEG)2-γE G)2, γE-(PEG)2-γE-(PEG)2, γE-(PEG)4, γE-γE, γE-γE-(O2Oc), γE-γE-(O2Oc)-(O2Oc), γE- γE-(PEG)12, γE-γE-(PEG)2-(PEG)2, γE-γE-(PEG)2-γE-γE, γE-γE-(PEG)4 and γE-γE-(PEG)8. In some aspects, the linker is selected from γE, γE-(O2Oc)-(O2Oc), and γE-γE(O2Oc)-(O2Oc)-γE-γE.

[0171] In some aspects, the peptide comprises any one of SEQ ID NOs: 207-347 and 532-537. In some aspects, the peptide comprises SEQ ID NO: 228. In some aspects, the peptide comprises SEQ ID NO: 233.

[0172] In some aspects, the peptide has Figure 4A-4B In some aspects, the peptide has Figure 4A In some aspects, the peptide has Figure 4B structure.

[0173] In some aspects, the peptide is any one of the peptides in Table 2.

[0174] Table 2. Peptides modified at position 20

[0175]

[0176]

[0177]

[0178]

[0179]

[0180]

[0181]

[0182]

[0183]

[0184]

[0185]

[0186]

[0187]

[0188]

[0189]

[0190]

[0191]

[0192]

[0193]

[0194]

[0195]

[0196]

[0197]

[0198]

[0199]

[0200]

[0201]

[0202]

[0203]

[0204]

[0205]

[0206]

[0207] In some aspects, the peptide comprises the sequence: X1-X2-X3-G-X5-X6-TSD-X10-SK-X13-L-X15-X16-X17-X18-X19-X20-X21-X22-X23-X24-X25-X26-X27-X28-X29-X30-X31-Z, wherein X1 is H or ((1H-imidazol-4-yl)methyl)glycine (NHis), X2 is S or aminoisobutyric acid (Aib), X3 is Q, H or I, X5 is T or S, X6 is F or α-methyl-phenylalanine (αMePhe), X10 is Y or V, and X13 is Y, αMePhe , Aib or diphenylalanine (Dip), X15 is D or E, X16 is S, E or L, X17 is R, Q or E, X18 is R, A or Aib, X19 is A or V, X20 is Q or R, X21 is D or L, X22 is F or αMePhe, X23 is V or I, X24 is Q or K, wherein K may comprise an acyl moiety and / or may be lipidated, X25 is W, Aib or S, X26 is L or I, X27 is M, V, L or A, X28 is N, E or Aib, X29 is T, Aib, G or absent, X30 is absent, Aib or G, X31 is absent or G, and Z is an amide or an acid (SEQ ID NO:415), wherein the peptide does not comprise SEQ ID NO:1.

[0208] In some aspects, the residue at position 24 is acylated. In some aspects, the residue at position 24 is lipidated. In some aspects, the lipid is selected from palmitoyl, stearoyl, lauryl, myristoyl, heptadecanoyl, octadecanedioic acid (C18 diacid) and eicosanedioic acid (C20 diacid). In some aspects, the lipid is selected from octadecanedioic acid (C18 diacid) and eicosanedioic acid (C20 diacid).

[0209] In some aspects, the lipid attached to the residue at position 24 is attached via a linker. In some aspects, the linker is selected from (O2Oc), (O2Oc)-(O2Oc), (O2Oc)-γE-(O2Oc), (PEG)2-(PEG)2-γE-γE, (PEG)2-γE-(PEG)2-γE, γE, γE-(O2Oc), γE-(O2Oc)-(O2Oc), γE-(O2Oc)-γE-(O2Oc), γE-(PEG)2-(PEG)2-γE G)2, γE-(PEG)2-γE-(PEG)2, γE-(PEG)4, γE-γE, γE-γE-(O2Oc), γE-γE-(O2Oc)-(O2Oc), γE- γE-(PEG)12, γE-γE-(PEG)2-(PEG)2, γE-γE-(PEG)2-γE-γE, γE-γE-(PEG)4 and γE-γE-(PEG)8. In some aspects, the linker is selected from γE, γE-(O2Oc)-(O2Oc), γE-γE-(PEG)2-(PEG)2, γE-γE-(PEG)2-γE-γE, and γE-γE-(O2Oc)-(O2Oc).

[0210] In some aspects, the peptide comprises the sequence: H-aminoisobutyric acid (Aib)-QGTFTSDVSK-αmethyl-phenylalanine (αMePhe)-L-X15-X16-RRAQDFVKWL-X27-X28-X29-X30-Z, wherein X15 is D or E, X16 is S or L, X27 is V or L, X28 is E or Aib, X29 is T, Aib or G, X30 is G or Aib or is not present, and Z is an amide or an acid (SEQ ID NO: 416).

[0211] In some aspects, the lysine at position 24 is acylated. In some aspects, the lipid is selected from palmitoyl, stearoyl, lauryl, myristoyl, heptadecanoyl, octadecanedioic acid (C18 diacid) and eicosanedioic acid (C20 diacid). In some aspects, the lysine at position 24 is lipidated. In some aspects, the lipid is octadecanedioic acid (C18 diacid).

[0212] In some aspects, the lipid is linked to the lysine at position 24 via a linker. In some aspects, the linker is selected from (O2Oc), (O2Oc)-(O2Oc), (O2Oc)-γE-(O2Oc), (PEG)2-(PEG)2-γE-γE, (PEG)2-γE-(PEG)2-γE, γE, γE-(O2Oc), γE-(O2Oc)-(O2Oc), γE-(O2Oc)-γE-(O2Oc), γE-(PEG)2-(PEG)2-γE G)2, γE-(PEG)2-γE-(PEG)2, γE-(PEG)4, γE-γE, γE-γE-(O2Oc), γE-γE-(O2Oc)-(O2Oc), γE- γE-(PEG)12, γE-γE-(PEG)2-(PEG)2, γE-γE-(PEG)2-γE-γE, γE-γE-(PEG)4 and γE-γE-(PEG)8. In some aspects, the linker is γE-(O2Oc)-(O2Oc).

[0213] In certain aspects, the GLP-1 / glucagon agonist peptides as disclosed have desirable potency at the glucagon and GLP-1 receptors.

[0214] In some aspects, the peptide comprises any one of SEQ ID NOs: 348-395.

[0215] In some aspects, the peptide is any one of the peptides in Table 3.

[0216] Table 3. Peptides modified at position 24

[0217]

[0218]

[0219]

[0220]

[0221]

[0222]

[0223]

[0224]

[0225]

[0226]

[0227]

[0228]

[0229]

[0230] In some aspects, the peptide comprises the sequence: H-X2-X3-G-X5-X6-TSD-X10-SK-X13-LDS-X17-X18-AQD-X22-V-X24-X25-X26-X27-NTX(30)-X(31)-Z, wherein X2 is S or aminoisobutyric acid (Aib), X3 is Q or H, X5 is T or S, X6 is F or α-methylphenylalanine (αMePhe), and X10 is Y, V or K, wherein K may comprise an acyl group. moiety and / or can be lipidated, X13 is Y, αMePhe, I or diphenylalanine (Dip) or K, wherein K can contain an acyl moiety and / or can be lipidated, X17 is R, Q or β-dimethylarginine (β-diMeArg), X18 is R or A, X22 is F or αMePhe, X24 is Q or E, X25 is W, Aib or H, X26 is L or I, X27 is M or A, X(30) is absent, X(31) is absent, and Z is an amide or an acid (SEQ ID NO:417), wherein the peptide does not comprise SEQ ID NO:1.

[0231] In some aspects, the residue at position 10 or 13 is acylated. In some aspects, the residue at position 10 or 13 is esterified. In some aspects, the lipid is selected from palmitoyl, stearoyl, lauryl, myristoyl, heptadecanoyl, octadecanoic acid (C18 diacid) and eicosanedioic acid (C20 diacid). In some aspects, the lipid is selected from octadecanoic acid (C18 diacid) and eicosanedioic acid (C20 diacid), stearoyl and palmitoyl.

[0232] In some aspects, the lipid attached to the residue at position 10 or 13 is attached via a linker. In some aspects, the linker is selected from (O2Oc), (O2Oc)-(O2Oc), (O2Oc)-γE-(O2Oc), (PEG)2-(PEG)2-γE-γE, (PEG)2-γE-(PEG)2-γE, γE, γE-(O2Oc), γE-(O2Oc)-(O2Oc), γE-(O2Oc)-γE-(O2Oc), γE-(PEG)2-(PEG)2-γE G)2, γE-(PEG)2-γE-(PEG)2, γE-(PEG)4, γE-γE, γE-γE-(O2Oc), γE-γE-(O2Oc)-(O2Oc), γE- γE-(PEG)12, γE-γE-(PEG)2-(PEG)2, γE-γE-(PEG)2-γE-γE, γE-γE-(PEG)4 and γE-γE-(PEG)8. In some aspects, the linker is selected from γE-γE-(O2Oc)-(O2Oc), γE-(O2Oc)-(O2Oc), γE-γE-(PEG)2-(PEG)2, and γE-(PEG)2-(PEG)2.

[0233] In some aspects, the peptide comprises any one of SEQ ID NOs: 396-411.

[0234] In some aspects, the peptide is any one of the peptides in Table 4 or Table 5.

[0235] Table 4. Peptides modified at position 10

[0236]

[0237]

[0238]

[0239] Table 5. Peptides modified at position 13

[0240]

[0241]

[0242]

[0243] In some aspects, the peptide comprises the sequence: H-X2-X3-G-X5-X6-TSD-X10-S-X12-αmethyl-phenylalanine (αMePhe)-L-X15-X16-X17-X18-A-X20-X21-X22-X23-X24-X25-X26-X27-X28-X29-X30-X31-Z, wherein X2 is aminoisobutyric acid (Aib), S or A, X3 is Q, H or E, X5 is T or S, X6 is F or αMePhe, X10 is V, K or Y, X1 In the present invention, X1 is S, X12 is K, E or S, X15 is D or E, X16 is T, S or G, X17 is K, R, E or Q, X18 is R or A, X20 is R, K or Q, X21 is D or E, X22 is αMePhe or F, X23 is V or I, X24 is Q or A, X25 is Aib or W, X26 is L or I, X27 is L, A, E, V or M, X28 is E, N, A, R or K, X29 is Aib, T or G, X30 is G, R or absent, X31 is G or absent, and Z is an amide or an acid (SEQ ID NO: 540).

[0244] In some aspects, X2 is Aib. In some aspects, X3 is Q. In some aspects, X3 is H. In some aspects, X5 is T. In some aspects, X5 is S. In some aspects, X6 is F. In some aspects, X6 is αMePhe. In some aspects, X10 is V. In some aspects, X12 is K. In some aspects, X15 is D. In some aspects, X16 is T. In some aspects, X16 is S. In some aspects, X17 is K. In some aspects, X17 is R. In some aspects, X18 is R. In some aspects, X18 is A. In some aspects, X20 is R. In some aspects, X20 is K. In some aspects, X21 is D. In some aspects, X22 is F. In some aspects, X22 is αMePhe. In some aspects, X23 is V. In some aspects, X24 is Q. In some aspects, X25 is W. In some aspects, X25 is Aib. In some aspects, X26 is L. In some aspects, X26 is I. In some aspects, X27 is L. In some aspects, X27 is A. In some aspects, X28 is E. In some aspects, X28 is N. In some aspects, X29 is Aib. In some aspects, X29 is T. In some aspects, X30 is G. In some aspects, X30 is absent. In some aspects, X31 is absent. In some aspects, Z is an amide. In some aspects, Z is an acid.

[0245] In some aspects, X2 is Aib, X12 is K, and X24 is Q. In some aspects, X16 is T, X17 is K, X27 is L, X28 is E, and X29 is Aib.

[0246] In some aspects, X3 is Q, X5 is T, X6 is F, X10 is V, X12 is K, X15 is D, X16 is T, X17 is K, X18 is R, X20 is R, X21 is D, X22 is F, X23 is V, X24 is Q, X25 is W, X26 is L, X27 is L, X28 is E, X29 is Aib, X30 is G, and X31 is absent.

[0247] In some aspects, X3 is H, X5 is S, X6 is αMePhe, X10 is V, X12 is K, X15 is D, X16 is S, X17 is R, X18 is A, X20 is K, X21 is D, X22 is αMePhe, X23 is V, X24 is Q, X25 is Aib, X26 is I, X27 is A, X28 is N, X29 is T, X30 is absent, and X31 is absent.

[0248] In some aspects, one or more lysine residues are acylated. In some aspects, the lysine at position 17 is acylated. In some aspects, the lysine at position 20 is acylated.

[0249] In some aspects, one or more lysine residues are lipidated. In some aspects, the lysine at position 17 is lipidated. In some aspects, the lysine at position 20 is lipidated.

[0250] In some aspects, the lipid is selected from octadecanedioic acid (C18 diacid) and eicosanedioic acid (C20 diacid). In some aspects, the lipid is octadecanedioic acid (C18 diacid). In some aspects, the lipid is eicosanedioic acid (C20 diacid).

[0251] In some aspects, the lipid is linked to the residue at position 17 or 20 via a linker. In some aspects, the linker is γE-(O2Oc)-(O2Oc) or γE-γE-(O2Oc)-(O2Oc). In some aspects, the linker is γE-(O2Oc)-(O2Oc). In some aspects, the linker is γE-γE-(O2Oc)-(O2Oc). In some aspects, the linker is linked to the epsilon amino group of the residue at position 17 or 20.

[0252] Certain aspects of the present disclosure relate to peptides comprising the sequence of H-Aib-QGTFTSDVSK-αMePhe-LDTKRARDFVQW-LL-E-Aib-G-acid (SEQ ID NO: 541).

[0253] In some aspects, the lysine at position 17 is acylated and lipidated, with the lipid being linked to the acylated lysine via (ε-(O2Oc)-(O2Oc)-γE-C18 diacid).

[0254] In some aspects, the lysine at position 17 is acylated and lipidated, and the lipid is linked to the acylated lysine at position 17 via (ε-(O2Oc)-(O2Oc)-γE-C20 diacid).

[0255] Certain aspects of the present disclosure relate to a peptide comprising the sequence H-Aib-HGS-αMePhe-TSDVSK-αMePhe-LDSRAAK(ε-(O2Oc)-(O2Oc)-γE-C18 diacid)20-D-αMePhe-VQ-Aib-IANT-amide (SEQ ID NO: 228).

[0256] Certain aspects of the present disclosure relate to a peptide comprising the sequence H-Aib-HGS-αMePhe-TSDVSK-αMePhe-LDSRAAK(ε-(O2Oc)-(O2Oc)-γE-γE-C20 diacid)20-D-αMePhe-VQ-Aib-IANT-amide (SEQ ID NO: 233).

[0257] In some aspects, the peptide binds to a GLP-1 receptor (GLP-1R), to a glucagon receptor (GCGR), or to both a GLP-1 receptor and a glucagon receptor. In some aspects, the GLP-1R is a human GLP-1R. In some aspects, the GCGR is a human GCGR. In some aspects, the peptide is an agonist of GLP-1 activity, an agonist of glucagon activity, or an agonist of both GLP-1 activity and glucagon activity.

[0258] In some aspects, the peptides have increased resistance to proteolysis relative to the natural ligands of GLP-1R and / or GCGR.

[0259] In some aspects, the peptide is isolated.

[0260] In some aspects, the peptide has at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% intact peptide remaining after incubation with a protease at 37° C. for 5 minutes, 10 minutes, 15 minutes, 30 minutes, 2 hours, 4 hours, or 24 hours. In some aspects, the protease is selected from enkephalinase, pepsin, pancreatin, simulated gastric fluid with pepsin, and simulated intestinal fluid with pancreatin.

[0261] In some aspects, the peptide has a half-life in cynomolgus monkeys after intravenous administration of at least 45 hours, at least 50 hours, at least 60 hours, at least 70 hours, at least 80 hours, at least 90 hours, at least 100 hours, at least 110 hours, at least 120 hours, or about 130 hours.

[0262] In some aspects, the peptide has a subcutaneous bioavailability of at least 75%, at least 80%, at least 90%, or about 95% in cynomolgus monkeys.

[0263] III. Methods for preparing GLP-1 / glucagon agonist peptides

[0264] The GLP-1 / glucagon agonist peptides for the purposes provided herein can be prepared by any suitable method. For example, in some aspects provided herein, by methods well known to those of ordinary skill in the art, such as by solid phase synthesis as described by Merrifield (1963, J.Am.Chem.Soc.85:2149-2154), the GLP-1 / glucagon agonist peptides for the purposes provided herein are chemically synthesized. Solid phase peptide synthesis can be accomplished, for example, by using an automatic synthesizer, using standard reagents, for example, as explained in Example 1 of WO 2014 / 091316, which is incorporated herein by reference in its entirety.

[0265] Alternatively, the GLP-1 / glucagon agonist peptides for the purposes provided herein can be recombinantly produced using convenient vector / host cell combinations as are well known to those of ordinary skill in the art. Various methods for recombinantly producing GLP-1 / glucagon agonist peptides are available. Typically, a polynucleotide sequence encoding a GLP-1 / glucagon agonist peptide is inserted into an appropriate expression vector, such as a vector containing the necessary elements for transcription and translation of the inserted coding sequence. The nucleic acid encoding the GLP-1 / glucagon agonist peptide is inserted into the vector in a suitable reading frame. The expression vector is then transfected into a suitable host cell that will express the GLP-1 / glucagon agonist peptide. Suitable host cells include, but are not limited to, bacteria, yeast, or mammalian cells. Various commercially available host-expression vector systems can be used to express the GLP-1 / glucagon agonist peptides described herein.

[0266] Pharmaceutical composition

[0267] Further provided are compositions, such as pharmaceutical compositions containing an effective amount of a GLP-1 / glucagon agonist peptide as provided herein, formulated for treating a metabolic disease, such as obesity, type 2 diabetes, and / or NASH.

[0268] The compositions of the present disclosure can be formulated according to known methods. Suitable preparation methods are described in, for example, Remington's Pharmaceutical Sciences, 19th edition, edited by A.R. Gennaro, Mack Publishing Co., Easton, PA (1995), which is incorporated herein by reference in its entirety. The compositions can be in various forms, including, but not limited to, aqueous solutions, emulsions, gels, suspensions, freeze-dried forms, or any other form known in the art. In addition, the compositions can contain pharmaceutically acceptable additives, including, for example, diluents, adhesives, stabilizers, and preservatives. Once formulated, the compositions of the present invention can be administered directly to a subject.

[0269] In some aspects, the pharmaceutical composition is a solid composition. In some aspects, the pharmaceutical composition is a liquid composition.

[0270] IV. Methods of Using GLP-1 / Glucagon Agonist Peptides

[0271] As provided herein, GLP-1 / glucagon agonist peptides can be used to improve glycemic control, reduce body weight, type 2 diabetes mellitus (T2DM), and / or treat or prevent nonalcoholic steatohepatitis (NASH).

[0272] In some aspects, administration of a GLP-1 / glucagon agonist peptide reduces body weight in a subject, increases insulin secretion in a subject, delays gastric emptying in a subject, reduces food intake in a subject, enhances mitochondrial function in a subject, inhibits de novo lipogenesis in a subject, reduces HbA1c in a subject, enhances fat oxidation in a subject, reduces hepatic mitochondrial oxidative stress in a subject, reduces steatosis in a subject, reduces fibrosis in a subject, reduces glycogen synthesis in a subject, increases gluconeogenesis in a subject, arrests disease progression in a subject, reverses fibrosis in a subject, and / or reduces the risk of death in a subject due to cirrhosis, hepatocellular carcinoma, and / or cardiorenal disease.

[0273] As provided herein, methods of improving glycemic control or reducing body weight in a human subject with T2DM and / or NASH can include administering a GLP-1 / glucagon agonist peptide to the subject.

[0274] The present disclosure also provides GLP-1 / glucagon agonist peptides for use in the manufacture of a medicament for improving glycemic control or reducing body weight in human subjects with T2DM and / or NASH.

[0275] In some aspects, the peptide is administered about once a week.

[0276] In some aspects, GLP-1 / glucagon agonist peptides are administered to treat or prevent a disease or condition caused by or characterized by being overweight. In some aspects, the disease or condition is obesity. In some aspects, the disease or condition is type 2 diabetes.

[0277] In some aspects, GLP-1 / glucagon agonist peptides are used to treat or non-alcoholic fatty liver disease (NASH). In some aspects, GLP-1 / glucagon agonist peptides are used by injection. In some aspects, GLP-1 / glucagon agonist peptides are orally administered. In some aspects, the administration of GLP-1 / glucagon agonist peptides reduces the weight of the subject, increases the insulin secretion of the subject, delays the gastric emptying of the subject, reduces the food intake of the subject, enhances the mitochondrial function of the subject, inhibits the de novo lipogenesis of the subject, reduces the HbA1c of the subject, enhances the fat oxidation of the subject, reduces the oxidative stress of the liver mitochondria of the subject, reduces the fatty degeneration of the subject, reduces the fibrosis of the subject, reduces the glycogen synthesis of the subject, increases the gluconeogenesis of the subject, prevents the disease progression of the subject, reverses the fibrosis of the subject and / or reduces the death risk of the subject due to cirrhosis, hepatocellular carcinoma and / or cardiorenal disease. In some aspects, the subject is human. In some aspects, the peptide is administered about once a week.

[0278] Example

[0279] Example 1: Preparation of lipidated GLP-1 / glucagon dual agonist peptide analogs

[0280] Lipidated-GLP-1R / GCGR dual agonist peptides were synthesized as C-terminal corboxamide or carboxylic acid using rink amide MBHA resin (100-200 mesh) or Wang resin (100-200 mesh). All peptides were synthesized by using 9-fluorenylmethoxycarbonyl (Fmoc) / tert-butyl ( t Bu) protocol was prepared using automated synthesis on a PTI Prelude solid phase peptide synthesizer. The manufacturer supplied protocol was applied to couple the amino acids in N,N-dimethylformamide (DMF) and the Fmoc protecting group was deprotected using piperidine (20% v / v) in DMF. Asparagine (Asn), glutamine (Gln) and histidine (His) were incorporated as their side chain triphenylmethyl (trityl (Trt) derivatives). Lysine (Lys) was incorporated as a side chain tert-butyloxycarbonyl (Boc) derivative. Serine (Ser), threonine (Thr) and tyrosine (Tyr) were incorporated as side chains. t Bu ether incorporation, and aspartate (Asp) and glutamate (Glu) as their side chains O tBu ester incorporation. Arginine (Arg) incorporation as a side chain 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbf) derivative. Other amino acids were incorporation with appropriate side chain protection.

[0281] When subsequent chemical modification of the lysine side chain was required, Lys(Mmt) was incorporated. Once the peptide chain extension was complete, the Mmt side chain protection was removed by treating the resin with 100 mL / mmol of a selective deprotection cocktail (1% trifluoroacetic acid (TFA), 5% TIPS in dichloromethane (DCM) for 1 min and repeated at least 10 times until the deprotection of the Mmt group was complete. The reaction was quenched with 10% N,N-diisopropylethylamine (DIPEA) / NMP. Subsequent coupling of albumin binding moieties such as lipids and linkers was performed manually in the presence of DIPEA using 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU) as a coupling agent.

[0282] By using TFA: triisopropylsilane (TIS): water (92.5.5: 2.5v / v) mixture with stirring treatment for 4 hours at room temperature, peptide is cleaved from solid support. After that, the cleavage mixture is filtered, vacuum concentrated, precipitated and washed with ether and the solid is separated by centrifugation. The crude peptide is dried under nitrogen flow and dissolved in 20% acetonitrile (MeCN) / water (v / v) and filtered. The crude peptide is purified as follows: on Varian SD-1Prep Star binary pump system, preparative reverse phase high performance liquid chromatography (RP-HPLC) is used, monitored by ultraviolet (UV) absorption at 210nm, using Xbridge C18-A stationary phase (19.0×250mm, 5 microns) column, 25-70% MeCN (0.1% TFA v / v) in water (0.1% TFA v / v) linear solvent gradient eluted during 25min. The purified fractions are merged, frozen and freeze-dried.

[0283] Liquid chromatography / mass spectrometry (LC / MS) characterization of the purified peptides was performed on a Waters MassLynx 3100 platform using an XBridge C18 stationary phase (4.6×100 mm, 3 microns) with a linear binary gradient of 10-90% MeCN (0.1% TFA v / v) in water (0.1% TFA v / v) eluted at 1.5 mL / min over 10 minutes at ambient temperature. Analytes were detected by both UV absorption at 210 nm and ionization using a Waters 3100 mass detector (electrospray ionization (ESI) + mode). Analytical RP-HPLC characterization was performed on an Agilent 1260 Infinity system using an Agilent Polaris C8-A stationary phase (4.6×100 mm, 3 microns) with a linear binary gradient of 10-90% MeCN (0.1% TFA v / v) in water (0.1% TFA v / v) eluting at 1.5 mL / min over 15 minutes at 40° C.

[0284] Example 2: In vitro functional assay of GLP-1 receptor and glucagon receptor

[0285] The functional activities of the lipidated-GLP-1R / GCGR peptides, such as cAMP production, were tested in CHO cell lines with stable recombinant expression of the human GLP-1 receptor (hGLP-1R) or the human glucagon receptor (hGCGR).

[0286] Cryopreserved cell stocks were quickly thawed in a water bath, suspended in assay buffer (0.1% BSA (Sigma #A3059) in HBSS (Sigma #H8264) with 25 mM HEPES (pH 7.4) and 0.5 mM IBMX (Sigma #17018)) and centrifuged at 240 x g for 5 minutes. The cells were plated at a batch-dependent optimized concentration (typically 1 x 10 hGLP-1R cells). 5 cells / mL, hGCGR cells are 2×10 5 Resuspend the cells in assay buffer (100 cells / mL).

[0287] Using a non-contact liquid dispenser (ECHO TM, LabCyte), test peptide stocks were prepared in DMSO and serially diluted in assay buffer to prepare 11-point concentration response curves in duplicate in 384-well low-volume microtiter assay plates (Corning #4514). Cells were added to the assay plates using a multidrop dispenser and incubated for 30 minutes at room temperature before measuring cAMP levels using the cAMP dynamic 2 homogeneous time resolved Fluorescence (HTRF) kit (CisbioBioassays #62AM4PEJ) following a two-step protocol according to the manufacturer's recommendations. Briefly, anti-cAMP cryptate (donor fluorophore) and cAMP-d2 (acceptor fluorophore) were prepared separately by diluting each 1:20 in the conjugation and lysis buffer provided in the kit. Anti-cAMP cryptate was added to all wells of the assay plate, followed by cAMP-d2 added to all wells except the non-specific binding (NSB) wells (to which conjugation and lysis buffer was added). The plates were incubated for one hour at room temperature and then read on an Envision (PerkinElmer) using an excitation wavelength of 320 nm and emission wavelengths of 620 nm and 665 nm.

[0288] Data were converted to % ΔF as described in the manufacturer's instructions and analyzed by a 4-parameter logistic fit to determine the EC 50 Values. The selectivity ratio of peptides for hGLP-1R versus hGCGR was defined as: % relative potency ratio = % GLP-1R activity relative to GLP-1 / % GlucR activity relative to glucagon. Data are shown as geometric mean EC from >n=2 independent experiments. 50 (pM).

[0289] The relative potency ratios of the peptides are listed in Tables 6-10.

[0290] Table 6. Potency of peptides with modifications at amino acid position 17

[0291]

[0292]

[0293]

[0294]

[0295]

[0296]

[0297]

[0298]

[0299]

[0300]

[0301] Table 7. Potency of peptides with modifications at the amino acid at position 20

[0302]

[0303]

[0304]

[0305]

[0306]

[0307] Table 8. Potency of peptides with modifications at the amino acid at position 24

[0308]

[0309]

[0310] Table 9. Potency of peptides with modifications at the amino acid at position 10

[0311]

[0312]

[0313] Table 10. Potency of peptides with modifications at amino acid position 13

[0314] Peptides <![CDATA[hGLP-1R EC 50 (pM)]]> <![CDATA[hGluc-R EC 50 (pM)]]> % Relative potency ratio 399 0.672 5.567 16.4 400 1.268 10.714 16.7 401 0.585 9.542 32.3 402 1.044 18.081 34.3 404 5.652 21.821 7.6 405 1041.139 8585.500 16.3 406 457.645 7308.311 31.6

[0315] Example 3: Acute food intake study in mice

[0316] Male C57Bl / 6 mice aged 8-9 weeks were obtained from Jackson Laboratories or Charles River, and one per cage was placed in a BioDaq (Research Diets) cage. The mice were placed on Alpha Dri bedding, standard chow diet (Envigo, 2018) and given water bags. Allow mice to acclimate for 1-2 weeks. Body weight was measured to ensure proper environmental adaptation. After acclimatization, mice were sham-administered at least 2 times before starting the food intake study. On the day of the study, mice were placed on a clean cage bottom, weighed and fasted for 6-8 hours. Mice were divided into groups based on average 24-hour food intake data and body weight. 1-2 hours before lights out, mice were subcutaneously administered with a vehicle or a test peptide dissolved in an appropriate vehicle at 5 mL / kg. The mice were undisturbed and allowed to obtain food and water for 48 hours. During this period of time, automatic food intake was monitored in the BioDaq system. Discrete food intake data were exported to MSExcel, thereby generating cumulative food intake data and analyzing them. Food intake at 24 hours (percent) compared to vehicle food intake is provided in Table 11.

[0317] Table 11. Food intake of mice administered lipidated peptides

[0318]

[0319]

[0320]

[0321] Example 4: Evaluation of the resistance of lipidated peptides to proteolysis by fasted irritant gastric juice (FasSSGF) containing porcine pancreatic pepsin

[0322] Freeze-dried porcine pancreatic pepsin (Sigma: P7012) was reconstituted to 0.5 mg / mL (~2500 units / mL) in freshly prepared FasSSGF (Biorelevant medium) to obtain an enzyme stock solution. The peptide stock solution was prepared to a concentration of 250 μM (about 1.0 mg / mL) in FasSSGF. 200 μL (10 μg, ~250 units) of pepsin stock solution was added to 200 μL of peptide solution (1.0 mg / mL, ~100 μg of peptide, ~25 nmol) and the mixture was co-incubated in a temperature-regulated incubator at 37°C for the duration of the experiment. 30 μL aliquots of the peptide-enzyme mixture were periodically removed (t=0, 5, 10, 15 and 30 min) and immediately quenched by adding 80 μL of a 0.1 M ammonium bicarbonate solution in water / acetonitrile (4:1, pH 8) to inhibit proteolytic activity. 30 μL aliquots were analyzed by analytical RP-HPLC. Analytical RP-HPLC method: Agilent Polaris C8-A column (4.6×100 mm, 3 microns) was eluted with a linear binary gradient of 10-90% MeCN (0.1% TFA v / v) in water (0.1% TFA v / v) at 1.5 mL min-1 at 40° C. over 10 or 15 min, with detection by UV absorption at 210 nm. Manual integration (AUC) allowed estimation of the remaining intact peptide during the experimental time course. Peptide stability data are provided in Table 12.

[0323] Table 12. Stability of lipidated peptides incubated with FasSSGF

[0324]

[0325]

[0326] Example 5: Evaluation of peptide resistance to proteolysis by neprilysin

[0327] 10.0 μg (~10 units) of recombinant enkephalinase (R&D Systems: 1182-ZNC-010) was reconstituted to 100 μL (100 μg / mL, ~100 units / mL) in assay buffer (50 mM Tris, 50 mM NaCl, 50 mM NaHCO3, adjusted to pH 8.3) to obtain an enzyme stock solution. The peptide stock solution was prepared in assay buffer to a concentration of ~250 μM (~1.0 mg / mL of 4 kDa peptide). 100 μL (10 μg, ~10 units) of the enkephalinase stock solution was added to 100 μL of the peptide stock solution (1.0 mg / mL, ~100 μg of peptide) and the mixture was co-incubated in a temperature-regulated incubator at 37°C for the duration of the experiment. 25 μL aliquots (~12.5 μg initial peptide) of the peptide-enzyme mixture were periodically removed (t=0, 30 min, 1 h, 2 h, 4 h and 24 h) and immediately quenched by adding an equal volume (75 μL) of 10% TFA (v / v) in 1:1 water / acetonitrile to inhibit proteolytic activity. The quenched aliquots were centrifuged at 7800 rpm and 30 μL of the supernatant was analyzed by analytical RP-HPLC as follows: Analytical RP-HPLC method: A linear binary gradient of 10-90% MeCN (0.1% TFA v / v) in water (0.1% TFA v / v) was used at 1.5 mL min during 10 or 15 min. -1 Elution was performed on an Agilent Polaris C8-A column (4.6 x 100 mm, 3 microns) at 40°C with detection by UV absorption at 210 nm. Manual integration (AUC) allowed estimation of remaining intact peptide during the experimental time course. Peptide stability data are provided in Table 13.

[0328] Table 13. Stability of lipidated peptides incubated with neprilysin

[0329]

[0330] Example 6: Evaluation of the resistance of monolipidated peptides to proteolysis in fasted simulated intestinal fluid (FasSSIF / pancreatin)

[0331] FasSSIF / P (Fasted State Simulated Intestinal Fluid + USP Pancreatin) ) was prepared as follows: According to Galia, Nicolaides, As described by Reppas and Dressman: Pharm. Res. 15 (1998) 698-705 and USP XL requirements. The preparation of FasSSIF / P is provided in Table 14. The resulting formulation was used immediately without storage.

[0332] Table 14. Preparation of FasSSIF / pancreatin

[0333]

[0334] The peptides to be evaluated (1.0 mg) were dissolved in pre-warmed trypsin-free Add fresh FasSSIF / trypsin to this The mixture was incubated for 10 min at 37 °C in a water bath with 10% MeCN (0.1% TFA v / v) for 3 min. (100 μL) was added to the reaction tube to start potential proteolysis. After the instantaneous vortex of the reaction tube, the mixture was incubated for the duration of the experiment in a constant temperature water bath at 37 °C. 25 μL aliquots of the peptide-enzyme mixture of the co-incubation were periodically taken out (t=0, 5, 10, 15 and 30 min), and quenched immediately to inhibit proteolytic activity by adding a solution (75 μL) of 10% TFA in 1:1 water / acetonitrile. The quenched sample was centrifuged (7800RPM, 3 min) to precipitate solids, and 10 μL aliquots of the supernatant solution were analyzed as follows using analytical RP-HPLC: Analytical RP-HPLC method: with a linear binary gradient of 10-90% MeCN (0.1% TFA v / v) in water (0.1% TFA v / v) at 1.5 mL min during 10 or 15 min. -1 Elution was performed on an Agilent Polaris C8-A column (4.6 x 100 mm, 3 microns) at 40°C with detection by UV absorption at 210 nm. Manual integration (AUC) allowed estimation of remaining intact peptide during the experimental time course. Peptide stability data are provided in Table 15.

[0335] Table 15. Stability of lipidated peptides incubated with FasSSIF.

[0336]

[0337]

[0338] Example 7: Glucose Levels in GLP-1R Knockout Mice Treated with GLP-1 / Glucagon Peptide

[0339] GLP-1R knockout (KO) and wild-type (WT) mice aged 8-14 weeks were housed individually and fed with standard chow (Envigo, 2918) and automatic drinking water. They were adapted to the environment for a minimum of 1-2 weeks and the mice were divided into groups based on body weight (n=4-8 / group). On the day of the study, the mice were briefly fasted for 2 hours before the start of the study. In some studies, mice were pretreated with octreotide (BaChem, 10 mg / kg) 30 minutes before peptide injection. Mice were dosed by subcutaneous injection, accompanied by peptide administration at the doses listed in Tables 16 and 17. Glucose was measured at various time points via a glucometer, including -30 min (before octreotide when used for the study), 0 min (before peptide administration), 30, 60, 120, 180, 240 and 360 minutes. Since these studies are acute in nature, mice are repeatedly used for multiple studies (no more than 3), and a washout period of at least a minimum of 1 week is always allowed. Glucose changes expressed as percent glucose change (at 60 or 120 min) since time 0 min are provided in Tables 16 and 17.

[0340] Table 16. Glucose changes in GLP-1R KO and WT mice treated with GLP-1 / glucagon peptides

[0341]

[0342]

[0343]

[0344]

[0345] Table 17. Glucose changes in GLP-1R KO and WT mice treated with GLP-1 / glucagon peptides

[0346]

[0347] Example 8: Pharmacokinetic characteristics in preclinical species

[0348] The pharmacokinetic (PK) properties of selected test peptides (n=8) after a single intravenous (iv) or subcutaneous (sc) administration in mice were characterized. A subset (n=4) that met the acceptance criteria was subsequently characterized in dogs (single intravenous administration) and non-human primates (single intravenous and subcutaneous administration). Blood sampling was performed at selected time points up to 48 hours in mice, up to 120 hours in dogs, and up to 168 hours in non-human primates after administration to accurately determine the complete pharmacokinetic profile of each species. Low-binding plastic containers were used during preparation and sample handling to avoid nonspecific binding.

[0349] Mouse: PK was studied in lean male C57BL / 6 (peptide 140, peptide 188, peptide 195, peptide 420, peptide 477 and peptide 472) or male C57BL / 6DIO pre-conditioned mice fed a high-fat diet (peptide 224, peptide 229). After administration, PK samples were collected from the dorsal plantar vein. The blood of each sample was transferred to a plastic microcentrifuge tube containing EDTA-K2, inverted several times for proper mixing of the contents and then placed on wet ice. The blood samples were centrifuged at 4°C to obtain plasma and stored at -75°C before analysis.

[0350] Dogs: PK was studied in non-naive male beagles. After dosing, PK samples were collected from the jugular vein. The blood of each sample was transferred to a plastic microcentrifuge tube containing EDTA-K2, inverted several times for proper mixing of the contents and then placed on wet ice. Plasma was separated by centrifugation and stored frozen in matrix tubes set to maintain a temperature of -20°C until analysis.

[0351] Non-human primates: PK was studied in non-naive male cynomolgus monkeys. After administration, PK samples were collected from the femoral vein. The blood of each sample was transferred to a plastic microcentrifuge tube containing EDTA-K2, inverted several times for proper mixing of the contents and then placed on wet ice. Within 30 minutes after sample collection, the blood samples were centrifuged under refrigeration (2°C to 8°C) conditions to obtain plasma and stored at -60°C to -90°C before analysis.

[0352] Formulation: Test articles were formulated in 20 mM sodium phosphate, 220 mM sorbitol pH 7.5 (peptide 224, peptide 229, peptide 140, peptide 188, peptide 195) or 20 mM sodium acetate 220 mM mannitol pH 4.5 (peptide 420, peptide 477, peptide 472).

[0353] Sample Analysis: Samples were analyzed by LC-MS / MS. Calibration standards were injected at the beginning and end of each batch, and the concentrations determined for each prepared standard were used to construct a calibration curve. Plasma and dose aliquot sample concentrations were determined from the plasma calibration curve.

[0354] Data analysis: Plasma concentration data were analyzed by non-compartmental analysis (NCA) using Phoenix Winnonlin v.8.3.3.33. The linear trapezoidal rule was used for increasing values, while the logarithmic trapezoidal rule was used for decreasing values, and uniform weighting was applied to the λ_z calculation. Subcutaneous bioavailability was calculated as AUC(sc) 0-inf / AUC(iv) 0-inf The reported values ​​(Table 18) represent the average of the individual estimates.

[0355] Results: Table 18 reports the half-life of the test peptides after intravenous administration and the absolute bioavailability after subcutaneous administration calculated by NCA. In general, the test peptides showed extended circulation half-lives in all preclinical species studied, and in addition, showed significant extensions in higher order species compared to rodents. The estimated half-life spanned 2.9-19 hours in mice, 86-71 hours in dogs, and 49-130 hours in non-human primates. The bioavailability after subcutaneous administration was generally ≥50%, with comparable levels in mice and non-human primates. The test peptides evaluated in non-human primates all showed high bioavailability of ≥75%.

[0356] Table 18. Preclinical PK. Half-life and absolute subcutaneous bioavailability of characterized test peptides following intravenous administration at indicated doses in mice, dogs and non-human primates.

[0357]

[0358] nd: Not determined.

Claims

1. A peptide comprising the sequence: H-X2-X3-G-X5-X6-TSD-X10-S-X12-α-methyl-phenylalanine (αMePhe)-L-X15-X16-X17-X18-A-X20-X21-X22-X23-X24-X25-X26-X27-X28-X29-X30-X31-Z, wherein X2 is aminoisobutyric acid (Aib), S or A, X3 is Q, H or E, X5 is T or S, X6 is F or αMePhe, X10 is V, K or Y, X12 is K, E or S, X15 is D or E, X16 is T, S or G, X17 is K, R, E or Q, X18 is R or A, X20 is R, K or Q, X21 is D or E, X22 is αMePhe or F, X23 is V or I, X24 is Q or A, X25 is Aib or W, X26 is L or I, X27 is L, A, E, V or M, X28 is E, N, A, R or K, X29 is Aib, T or G, X30 is G, R or does not exist. X31 is G or does not exist, and Z is an amide or an acid (SEQ ID NO: 540).

2. The peptide of claim 1, wherein X2 is Aib.

3. The peptide according to claim 1 or 2, wherein X3 is Q.

4. The peptide of claim 1 or 2, wherein X3 is H.

5. The peptide according to any one of claims 1 to 4, wherein X5 is T.

6. The peptide according to any one of claims 1 to 4, wherein X5 is S.

7. The peptide according to any one of claims 1 to 6, wherein X6 is F.

8. The peptide according to any one of claims 1 to 6, wherein X6 is αMePhe.

9. The peptide according to any one of claims 1 to 8, wherein X10 is V.

10. The peptide of any one of claims 1 to 9, wherein X12 is K.

11. The peptide according to any one of claims 1 to 10, wherein X15 is D.

12. The peptide of any one of claims 1 to 11, wherein X16 is T.

13. The peptide according to any one of claims 1 to 11, wherein X16 is S.

14. The peptide of any one of claims 1 to 13, wherein X17 is K.

15. The peptide of any one of claims 1 to 13, wherein X17 is R.

16. The peptide of any one of claims 1 to 15, wherein X18 is R.

17. The peptide of any one of claims 1 to 15, wherein X18 is A.

18. The peptide of any one of claims 1 to 17, wherein X20 is R.

19. The peptide of any one of claims 1 to 17, wherein X20 is K.

20. The peptide of any one of claims 1 to 19, wherein X21 is D.

21. The peptide of any one of claims 1 to 20, wherein X22 is F.

22. The peptide of any one of claims 1 to 20, wherein X22 is αMePhe.

23. The peptide of any one of claims 1 to 22, wherein X23 is V.

24. The peptide of any one of claims 1 to 23, wherein X24 is Q.

25. The peptide of any one of claims 1 to 24, wherein X25 is W.

26. The peptide of any one of claims 1 to 24, wherein X25 is Aib.

27. The peptide of any one of claims 1 to 26, wherein X26 is L.

28. A peptide as described in any one of claims 1 to 26, wherein X26 is 1.

29. The peptide of any one of claims 1 to 28, wherein X27 is L.

30. The peptide of any one of claims 1 to 28, wherein X27 is A.

31. The peptide of any one of claims 1 to 30, wherein X28 is E.

32. The peptide of any one of claims 1 to 30, wherein X28 is N.

33. The peptide of any one of claims 1 to 32, wherein X29 is Aib.

34. The peptide of any one of claims 1 to 32, wherein X29 is T.

35. The peptide of any one of claims 1 to 34, wherein X30 is G.

36. The peptide of any one of claims 1 to 34, wherein X30 is absent.

37. The peptide of any one of claims 1 to 36, wherein X31 is absent.

38. The peptide of any one of claims 1 to 36, wherein Z is an amide.

39. The peptide of any one of claims 1 to 36, wherein Z is an acid.

40. The peptide of claim 1, wherein X2 is Aib, X12 is K, and X24 is Q.

41. The peptide of claim 1, wherein X16 is T, X17 is K, X27 is L, X28 is E, and X29 is Aib.

42. The peptide of claim 1, wherein X3 is Q, X5 is T, X6 is F, X10 is V, X12 is K, X15 is D, X16 is T, X17 is K, X18 is R, X20 is R, X21 is D, X22 is F, X23 is V, X24 is Q, X25 is W, X26 is L, X27 is L, X28 is E, X29 is Aib, X30 is G, X31 is absent, and Z is an acid.

43. The peptide of claim 1, wherein X3 is H, X5 is S, X6 is αMePhe, X10 is V, X12 is K, X15 is D, X16 is S, X17 is R, X18 is A, X20 is K, X21 is D, X22 is αMePhe, X23 is V, X24 is Q, X25 is Aib, X26 is I, X27 is A, X28 is N, X29 is T, X30 is absent, X31 is absent, and Z is amide.

44. A peptide as claimed in any one of claims 1 to 43, wherein one or more lysine residues are acylated.

45. The peptide of claim 44, wherein the lysine at position 17 is acylated.

46. ​​The peptide of claim 44, wherein the lysine at position 20 is acylated.

47. A peptide as described in any one of claims 1 to 46, wherein one or more lysine residues are lipidated.

48. The peptide of claim 47, wherein the lysine at position 17 is lipidated.

49. The peptide of claim 47, wherein the lysine at position 20 is lipidated.

50. The peptide of any one of claims 47 to 49, wherein the lipid is selected from octadecanedioic acid (C18 diacid) and eicosanedioic acid (C20 diacid).

51. The peptide of claim 50, wherein the lipid is octadecanedioic acid (C18 diacid).

52. The peptide of claim 50, wherein the lipid is eicosanedioic acid (C20 diacid).

53. A peptide as described in any one of claims 44 to 52, wherein the lipid is linked to the epsilon amino group of lysine at position 17 or 20 via a linker.

54. The peptide of claim 53, wherein the linker is ((O2Oc)-(O2Oc)-γE) or ((O2Oc)-(O2Oc)-γE-γE) in the C-terminal to N-terminal direction.

55. The peptide of claim 53 or 54, wherein the linker is ((O2Oc)-(O2Oc)-γE) in the C-terminal to N-terminal direction.

56. The peptide of claim 53 or 54, wherein the linker is ((O2Oc)-(O2Oc)-γE-γE) in the C-terminal to N-terminal direction.

57. A peptide as described in any one of claims 53 to 55, wherein the linker is attached to the epsilon amino group of the residue at position 17 or at position 20.

58. A peptide comprising the sequence of H-Aib-QGTFTSDVSK-αMePhe-LDTKRARDFVQWLLE-Aib-G-acid (SEQ ID NO: 541).

59. The peptide of claim 58, wherein the lysine at position 17 is acylated and lipidated, the lipid being linked to the acylated lysine via the epsilon amino group of the acylated lysine linked to a ((O2Oc)-(O2Oc)-γE) linker in the C-terminal to N-terminal direction, and the lipid being octadecanedioic acid (C18 diacid).

60. The peptide of claim 58, wherein the lysine at position 17 is acylated and lipidated, the lipid being linked to the acylated lysine via the epsilon amino group of the acylated lysine linked to a ((O2Oc)-(O2Oc)-γE) linker in the C-terminal to N-terminal direction, and wherein the lipid is eicosanedioic acid (C20 diacid).

61. A peptide comprising the sequence H-Aib-HGS-αMePhe-TSDVSK-αMePhe-LDSRAAK(ε-(O2Oc)-(O2Oc)-γE-C18 diacid)20-D-αMePhe-VQ-Aib-IANT-amide (SE Q ID NO: 228).

62. A peptide comprising the sequence H-Aib-HGS-αMePhe-TSDVSK-αMePhe-LDSRAAK(ε-(O2Oc)-(O2Oc)-γE-γE-C20 diacid)20-D-αMePhe-VQ-Aib-IANT-amide (SEQ ID NO: 233).

63. The peptide of any one of claims 1 to 62, wherein the peptide binds to the GLP-1 receptor (GLP-1R), to the glucagon receptor (GCGR), or to both the GLP-1 receptor and the glucagon receptor.

64. The peptide of claim 63, wherein the GLP-1R is human GLP-1R.

65. The peptide of claim 63 or 64, wherein the GCGR is human GCGR.

66. The peptide of any one of claims 1 to 65, wherein the peptide is an agonist of GLP-1 activity, an agonist of glucagon activity, or an agonist of both GLP-1 activity and glucagon activity.

67. A peptide as described in any one of claims 1 to 66, wherein the peptide has increased resistance to proteolysis relative to the natural ligands of GLP-1R and / or GCGR.

68. The peptide of any one of claims 1 to 67, wherein the peptide is isolated.

69. A peptide as described in any one of claims 1 to 68, wherein the peptide has at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% intact peptide remaining after incubation with a protease at 37°C for 5 minutes, 10 minutes, 15 minutes, 30 minutes, 2 hours, 4 hours or 24 hours.

70. The peptide of claim 69, wherein the protease is selected from the group consisting of: enkephalinase, pepsin, pancreatin, simulated gastric fluid with pepsin, and simulated intestinal fluid with pancreatin.

71. A peptide as described in any one of claims 1 to 70, wherein the peptide has a half-life of at least 45 hours, at least 50 hours, at least 60 hours, at least 70 hours, at least 80 hours, at least 90 hours, at least 100 hours, at least 110 hours, at least 120 hours or about 130 hours in cynomolgus monkeys after intravenous administration.

72. The peptide of any one of claims 1 to 71, wherein the peptide has a subcutaneous bioavailability of at least 75%, at least 80%, at least 90% or about 95% in cynomolgus monkeys.

73. A pharmaceutical composition comprising the peptide of any one of claims 1 to 72.

74. The composition of claim 73, wherein the composition is a solid composition.

75. The composition of claim 73, wherein the composition is a liquid composition.